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Abstract 
The aim of this thesis was to investigate a dual method of targeting cancer 
cells with a nanoparticle system containing both a thermoresponsive corona 
and folate tag. The nanoparticle system used a ‘hide-and-reveal’ motif 
whereby the folate tag would only be revealed above the transition 
temperature of the thermoresponsive corona. 
There were difficulties encountered during the synthesis of poly(lactide-co-
glycolide) (PLGA) for the further polymerisation of the thermoresponsive 
copolymer therefore poly(lactide) (PLA) was synthesized as an alternative. 
The initial thermoresponsive polymer library synthesised (PLGA-b-
poly((polypropylene glycol methacrylate)-stat-(oligoethylene glycol 
methacrylate))) when assembled into nanoparticles had a transition 
temperature (Tt) of 40 – 65 °C and thus did not have a low enough Tt for the 
cell studies. A second polymer library (PLA-b-P((diethylene glycol 
methacrylate)-stat-(oligoethylene glycol methacrylate)), PLA-b-P(DEGMA-
stat-OEGMA)) when assembled into NPs had a Tt of between 28 – 78 °C when 
the DEGMA:OEGMA ratio was altered from 100:0 to 50:50. In addition to the 
thermoresponsive polymer library, three folate tagged amphiphilic polymers 
were synthesised. The polymers were PLA-b-polyethylene glycol (PLA-PEG) 
with a terminal folate. Each of the three PLA-PEGx polymers were synthesised 
with a different length of PEG, PEG450, PEG3k and PEG10k. 
A reproducible method of nanoparticle assembly was developed which 
produced nanoparticles of an average radius of  ̴100 nm when PLA-b-
P(DEGMA-stat-OEGMA) polymers were used. 
Three methods of controlling the overall aggregation temperature were put 
forward. By assembling NPs using one type of PLA-b-P(DEGMA-stat-OEGMA) 
the Tt of the NPs was dependent on the ratio of DEGMA:OEGMA. It was also 
possible to control the aggregation temperature by mixing two types of PLA-
b-P(DEGMA-stat-OEGMA) polymers (provided the difference in 
DEGMA:OEGMA between the two polymers was between 0 – 10 %). In 
addition by mixing PLA-b-P(DEGMA-stat-OEGMA) preformed NPs the 
aggregation temperature could be controlled similar to that for polymer 
blend NPs. 
The NPs were tested in both MCF-7 and HCT116 cell lines and were shown to 
have no adverse effect on the cell metabolism or membrane integrity when 
the NP concentration was below 4 mg/mL. It was found that there was in 
increase in uptake of the thermoresponsive NPs when incubation 
temperature was above the NPs Tt. When the PEG450 and PEG3k linked folate 
was used an increased uptake was observed in MCF-7 cells however no 
difference in uptake was observed in HCT116 cell line. 
Overall the ‘hide-and-reveal’ motif on this NP system was shown to be 
successful in enhancing the uptake in folate receptor positive cells. 
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19 Introduction 
1  Introduction 
Recent research in drug delivery has led to the development of new and 
innovative delivery systems.1 The need for these new systems stems from the 
ever increasing push to make drugs safer and more efficient. Various systems 
have been used for this purpose including liposomes, micelles, dendrimers 
and other polymeric particles. Many of these such types of nanoparticles have 
found a use within cancer treatments.2 
In general, there are many hurdles a drug molecule and carrier must 
overcome before it can cause a therapeutic response at the relevant site. 
Macrophages and the reticuloendothelial system (RES), as well as organs such 
as the kidneys and liver, cause rapid excretion from the bloodstream and thus 
lower bioavailability of drugs. With solid tumours comes another type of 
challenge, how to get the drug molecule to the cells when they are in a 
hypoxic (low oxygen) environment. This is caused by the lack of blood vessels 
to the innermost regions of the tumour. This, though, can offer an advantage 
for drug delivery due to the type of blood vessels that grow into the tumour 
area. This so called ‘leaky’ architecture, part of the enhanced permeability 
and retention (EPR) effect,3 allows for the accumulation of macromolecules, a 
possible target for nanoparticle drug delivery vehicles.  
A core-shell nanoparticle (CSP) is one such type of drug delivery and in certain 
circumstances diagnostic vehicle that has been developed to overcome the 
hurdles mentioned above. CSPs consist of a core to allow for the 
encapsulation or attachment, by chemically bonding the drug to the core, of 
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hydrophobic/poorly-soluble drug molecules, whilst the shell is hydrophilic for 
transport around the body in the bloodstream. Therefore allowing for longer 
circulation times and in turn increasing the bio-availability.4  
An advantage of these types of nanoparticles is that they are capable of being 
targeted both actively and passively.5  
1.1  Passive targeting 
Passive targeting of these drug delivery vehicles uses the EPR effect to allow 
large macromolecules and particles to be transported through the permeable 
vasculature surrounding solid tumours.6 The EPR effect is a characteristic of 
solid tumours which have elevated levels of permeability factors, such as 
nitric oxide and bradykinin.7,8 These permeability factors in conjunction with a 
proteinaceous vascular permeability factor (VPF) similar to vascular 
endothelial growth factor (VEGF),9 leads to the formation of leaky vasculature 
around solid tumours. This so called ‘leaky’ nature of the vasculature results 
in the extravasation of plasma proteins and most importantly of all, for drug 
delivery purposes, macromolecules and lipid particles. 
1.2  ‘Active’ targeting  
The so-called active targeting, where by a specific active site is targeted on 
the diseased cells using a ligand was first proposed over 100 years ago by Paul 
Ehrlich the founder of chemotherapy (for which he won the Nobel prize for 
Physiology or Medicine in 1908).10 Ehrlich’s proposed idea of using ‘magic 
bullets’ to seek out and treat only the diseased site has been the foundation 
for many research groups work over the last century. 
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The approach of active targeting is aimed at increasing the interactions 
between specific cells and the NPs targeting them, therefore enhancing the 
selectivity of the uptake and delivery of drugs without altering the overall 
biodistribution.11,12  
Numerous cancerous tumours overexpress certain factors which can be taken 
advantage of to target nanoparticles for site-specific uptake and drug 
delivery. One such over expressed factor is the folate receptor. It has been 
shown that by conjugating folate to a macromolecule uptake of the NP into 
tumour cells increases.13 This idea has been used by many research groups 
since this discovery and will be discussed later in this chapter.14-19 
CSPs have found a niche in so called ‘smart materials’ where, with the use of 
certain types of materials, the CSPs respond to different stimuli whether they 
are applied externally or through changes within the body. This use of stimuli-
responsive materials has allowed scientists to target the changes both within 
and surrounding tumour tissues as a method for treating the disease.  
In this introduction some of the recent examples of the use of stimuli-
responsive CSPs and the site specific targeting of said CSPs will be outlined. 
 
1.3  Types of Core 
There are 3 main types of core used for stimuli-responsive CSPs: iron 
(magnetic), gold and polymeric material, Figure 1. With each of these types of 
cores offering different characteristics dependant on what is required. 
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Figure 1 General schematic of three different types of CSPs. A) Gold CSP. B) Polymer CSP. C) 
Iron oxide CSP. Green star denotes drug/dye molecules. 
1.3.1  Inorganic 
1.3.1.1  Gold (Au NPs) 
Au NPs have recently found themselves to be a promising tool as a delivery 
agent as they have many desirable characteristics. Gold itself is essentially 
inert, non-toxic and so making it biocompatible.20,21 2 key aspects of Au NPs 
are that, firstly, they can be fabricated relatively easily in a range of core-sizes 
from 1 - 150 nm.22 Secondly, the high surface-to-volume ratio of Au NPs 
allows for incorporation of multiple shell types and targeting ligands.23 
With the possibilities of controlling the structure of the Au NPs, either spheres 
or nanorods, there has been interest in determining how these two 
morphologies affect the cell uptake. Arnida et al. tested both rod and sphere 
type NPs with a PEG shell for their toxicity and uptake in human prostate 
cancer cells.21 It was determined that neither morphologies had a detrimental 
effect on the cell viability however the smaller of the spheres (30 and 50 nm) 
were taken up to a higher extent than the larger (90 nm) spheres. For the 
rods the opposite was true whereby the larger of the rods (45 nm) showed an 
increased uptake when compared with the smaller (35 nm) rods. The group 
concluded that it was the core size and not the hydrodynamic volume that 
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determined the level of uptake. When similar particles were tested in vivo the 
nanorods with a PEG coating were taken up to a lesser extent by the liver 
than the PEGylated Au spheres.24 The geometry of the particles also had an 
effect on the uptake by macrophages as the PEGylate nanorods showed a 
significantly lower uptake than the spheres.   
Au NPs also offer an alternative option to other types of NPs as they can be 
heated due to a phenomenon known as surface plasmon resonance (SPR) 
whereby light energy is transformed into heat.25 This is advantageous as a 
treatment with gold particles alone as they can be used for thermal ablation 
therapy. By using gold nanorods, shown above to offer advantages over their 
spherical counterparts, local hyperthermia at tumour sites can be achieved. 
By injecting gold nanorods into mice Dickerson et al. showed that tumour 
growth could be inhibited by simply heating the nanorods with near infra-red 
light.26 Similar targeting and hyperthermia induced growth inhibition has 
been noted in vitro and in vivo by others as it becomes a burgeoning area for 
preclinical non-invasive cancer therapy.27-29 
Au has shown to be susceptible to external stimuli when grafted with specific 
types of polymers to form a shell. PNIPAM,30 thiol-terminal PEG,31 poly(acrylic 
acid) to form star block copolymers,32 and poly(vinyl pyridine)33 have all been 
used to form a responsive shell. The possibility of heating Au NPs is also 
advantageous when NPs are coated with a thermoresponsive polymer 
coating. The opportunity of specifically inducing a temperature switch 
through the heating of the Au NPs has been exploited by Barhoumi et al. to 
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enhance the uptake of gold shell NPs.34 By coating the gold shell with PNIPAM 
a peptide ligand attached to the gold surface could be revealed when the 
temperature was raised above the polymer’s transition temperature, thus 
offering a heightened NP uptake compared to non-targeted versions.  
Au NPs are never likely to offer long term use as a drug delivery vehicle due to 
a lack of hollow core and so removing the possibility of drug encapsulation. 
The need to chemically alter any drug molecules used in order to facilitate 
conjugation/adsorption to the Au surface or NP shell is also a weakness. The 
use of Au Ns in thermal treatments does however offer the possibility of this 
being a long term efficacious treatment without the need for small drug 
molecules to be attached. 
A similar type of inorganic particle uses an iron core, although it has similar 
disadvantages as Au it does have one major advantage as it can be used for 
diagnostics as well as uses in therapeutic areas.  
 
1.3.1.2  Iron Oxide (Magnetic)  
CSPs using a magnetic core (MCSP) can be used for both targeting and 
imaging.35,36 This stems for the recent increase in ‘theranostic’ agents, which 
allows both for the controlled release of a drug molecule and for imaging of 
the site using clinical techniques such as MRI37 due to iron being an effective 
contrast agent.  
As with for Au NPs, iron is used mostly as a solid core with the surface 
functionalised with different substances depending on what is required. Kievit 
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et al gave an example of using a drug loaded iron oxide NP coated with a PEG 
shell for the pH responsive delivery of DOX.38 Huang et al showed the guiding 
of MCSP (using superparamagnetic iron oxide nanoparticles with a shell of 
Pluronic F127 and poly(DL-lactide)) was enhanced when an external magnetic 
field was applied.39 
A recent alternative to the use of Fe as the entirety of the core is to use a 
poly(lactic-co-glycolic acid) (PLGA) core embedded with magnetite 
nanoparticles, thus offering the need for less iron to be present and using a 
biocompatible polymer for delivery.40 The Nguyen group previously used CSPs 
to be used for drug delivery using poly(N-isopropylacrylamide–acrylamide–
allylamine) (PNIPAAM-AAm-AH)-coated magnetic nanoparticles with PLGA as 
the shell.41 However, the magnetic particles were not all contained in the core 
and a portion was present on the surface which led to uncontrolled drug 
release and an inefficient drug delivery vehicle. Nguyen et al successfully 
synthesised the magnetic CSPs using a layer-by-layer technique and carried 
out both in-vitro and in-vivo studies. It was found that by using the targeting 
of Gly-Arg-Gly-Asp-Ser (GRGDS) peptides the uptake was increased over the 
bare MCSPs. While in-vivo investigations showed that with the use of a 
magnet the MCSPs accumulated exclusively at the tumour in a mouse model. 
The downside of using magnetic CSPs is using a magnet of sufficient strength 
to enable control at deep lying tumours can lead to adverse physiological 
effects.  
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To fulfil the potential of CSPs for use in the clinic organic/polymer core NPs 
offer the main route from benchtop to the hospital bed as the use of hollow 
cores can lead to higher drug transport than inorganic based CSPs. 
1.3.2   Organic 
There have been many different types of organic polymer materials used to 
make diverse forms of nanaoparticles over the last few decades.42-45 When 
amphiphilic block copolymers are used a CSP can be formed, the hydrophilic 
polymer forms a protective shell over the hydrophobic section which can in 
turn house hydrophobic guests, such as drugs and dyes. The functionalisation 
of polymers allows for the attachment of both targeting ligands14 and cell-
penetrating peptides46 to aid in the delivery.  
The focus of the remainder of this chapter will be on the use of these polymer 
CSPs due to the advantages with using organic/polymer core materials and 
the use of these as stimuli-responsive drug delivery vehicles.  
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1.4  Types of Stimuli 
 
Figure 2 Depiction of a core-shell nanoparticle. a) After a stimulus the shell becomes 'leaky' 
allowing for release of drug molecule. b) Complete degradation of shell to allow release of 
drug from core. 
 There are many stimuli used to initiate a response from smart material, Table 
1. 
Table 1 Types of stimuli that can be used to initiate a response from ‘smart’ 
materials. 
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Physical stimuli Chemical and biochemical stimuli 
Temperature Specific ions 
Ionic strength Chemical agents 
Solvents Host–guest interaction 
Magnetic field Antigen–antibody interaction 
Electric field Enzyme substrates 
Electromagnetic 
radiation (UV, visible) Affinity ligands 
Mechanism stress, 
strain Other biochemical agents 
 
 
 
Below we will focus on two of the types of local stimuli used to bring about 
the site specific release of CSPs cargo, temperature and local pH changes. 
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Both changes in temperature and pH can be brought about either by the 
clinician or by taking advantages of local changes of tumour tissue. 
1.4.1  Temperature 
Thermoresponsive polymers represent one of the most common sub-groups 
of ‘smart’ polymers; these possess an upper (UCST) and lower critical solution 
temperature (LCST) in aqueous media.34,48,49 The LCST is the critical point at 
which the hydrogen bonds between the polymer and the surrounding water 
molecules break,50 leading to a decrease in colloidal stability of the polymer 
chains and thus phase separation occurring in an entropy driven process due 
to the loss of water molecules. The phase separation results in the formation 
of a ‘polymer-rich’ and a ‘polymer-poor’ phase which can be characterised by 
the bulk aggregation of the polymer/particles present. 
One such polymer is poly(N-isopropylacrylamide) (PNIPAM) and has been one 
of the most heavily researched thermoresponsive polymers due to a LCST 
close to body temperature, ~32 °C and that its LCST is relatively insensitive to 
environmental conditions; providing scope for PNIPAM use in vivo and the 
use of which has already been covered in numerous reviews.51,52  
The Takao Aoyagi lab conducted a study using PNIPAM to open up a new 
possibility of effective and facile encapsulation targeting and triggered release 
of drugs.53 Three series of copolymers with different polymer structures, all 
with PNIPAM as a common denominator, were successfully synthesised by 
reversible addition–fragmentation chain transfer (RAFT) polymerisation, 
Figure 3. 
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Figure 3 Schematic representation of the multi-stimuli-responsive nano- assembly by 
mixing of selected block copolymers with the common temperature-responsive segment 
and heating/cooling. 
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They found that with simple mixing of the different block copolymers the 
distinct two-step temperature response behaviour, due to the different LCSTs 
of each block, made this system considerably advantageous over self-
assembly of the one block copolymer system, Figure 4. 
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Figure 4 Temperature-dependent behavior of 0.1 w/v% aqueous solution of (O) 
P(NIPAAm112-co-HMAAm14)-b-P(NIPAAm54-co-BMAAm12), () PEO113-b-P(NIPAAm85-co-
BMAAm19), and () PLAMA2-b- P(NIPAAm79-co-HMAAm35)-b-P(NIPAAm28-co-BMAAm6).
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Thermo- and pH-sensitive polyion complex (PIC) micelles were formed from 
two oppositely charged diblock copolymer based on PNIPAM by Guiying Li 
and colleagues.54 
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Figure 5 The proposed schematic representation of drug-loaded PIC micelles.
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The chitosan (CS)/poly acrylic acid (PAA) layer of these micelles, Figure 5, 
successfully protected the encapsulated doxorubicin (DOX) drug in neutral 
conditions. However, once the pH dropped or the temperature was raised 
above LCST the sensitive PNIPAM chains collapse, leading to the rapid 
sustained release of DOX due to the differences in electrostatic interactions 
between the micelles and the DOX; when these were minimised, upon 
PNIPAM collapse and low pH the DOX was released rapidly from the micelles. 
Both of the above examples using PNIPAM show it to be an accomplished 
thermoresponsive polymer system. A possible drawback however is that the 
systems are responsive to both pH and temperature which could lead to 
insufficient control on the site specific delivery. As the advantage of PNIPAM 
is the readily altered LCST to a range needed which has led to multiple 
research groups choosing this polymer, it must be considered that questions 
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have been brought against it in relation to its possible cytotoxic effects, as 
well as phase transition hysteresis and a significant end group influence on 
thermal behaviour. 55-57 
As an alternative to PNIPAM, Wei et al synthesised a new type of monomer to 
form a thermoresponsive block copolymer.58 Poly(N-(N-Boc-
ethylenediamine)methacryloylglycylglycylamide) (PBEMAGG) was synthesised 
from MAGG-COOH and N-Boc-ethylenediamine and copolymerised with a 
PEG-chain transfer agent. It was found the precise control of the LCST could 
be regulated by altering the number of pendant BOC groups. When 
temperature is below the LCST, the hydrogen bonds between amide groups 
and water ensure the stability of the particles. When the temperature is 
above LCST, the hydrogen bonds are broken by tert-butyl groups which are 
hydrophobic groups in each PBEMAGG repeat unit, so the solubility of 
polymers declines.59 
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Figure 6 The UV transmission percentage of PEG2k-b-PBEMAGG with different PBEMAGG 
block lengths at different temperatures. The UV wavelength is 400 nm. The concentration 
of sample is 1.5mg/mL in water. The PBEMAGG block length was denoted by its number-
average molecular weight (Mn determined by 
1
H NMR analysis).
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As the temperature increases, the hydrophobicity of PBEMAGG increases; 
leading to the deformation of the micelle, thus the release of the drug cargo. 
A more recent type of polymer containing an LCST suitable for in vitro and in 
vivo offering similar advantages to that of PNIPAM but with few of the 
drawbacks are combinations of oligo(ethylene glycol methacrylate) 
(OEGMA).60,61 PNIPAM exhibits broad hysteresis on cooling, most likely as a 
result of the PNIPAM globules exhibiting intra- and intermolecular hydrogen 
bonding and high Tg; OEGMA based polymers though do not undergo any 
intermolecular hydrogen bonding and thus limited hysteresis is exhibited.62 
POEGMA offers further advantages over PNIPAM in that the molar mass of 
the polymer does not have a significant effect on the transition temperature. 
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It is the hydrophilic-hydrophobic balance of the OEGMA monomer units 
which allows for the precise control of the transition.63 
The precise control of transition temperatures that is possible for POEGMA 
led to the synthesis of poly((diethylene glycol methacrylate)-co-OEGMA) 
(P(DEGMA-co-OEGMA)) brushes on silicon wafers.64 When the polymer chains 
were extended at low temperatures a good resistance to protein adsorption 
was observed. Further anti-fouling properties were also observed by Chilkoti 
et al.;65,66 this is a critical point if these polymers are to be used to enable long 
circulation time of NPs.  
The use of OEGMA-based polymers within colloids has grown recently with 
various uses such as triggers for assembly/disassembly of dendritic 
elements,67 vesicles as cell mimics68 and drug delivery.69  
Recent uses of POEGMA copolymerised with polycaprolactone in a star shape 
allowed for loose micelles to be formed with non-interacting cores.70 These 
micellar NPs were capable of encapsulating doxorubicin and also shown to 
have no adverse reaction with human blood, in terms of whole blood 
viscosity, erythrocyte aggregation, and haemolysis. Much like most groups 
working in the drug delivery field enhancing the encapsulation of small 
molecule drugs was to be the focus of future research to enable improvement 
of this NP type as a drug delivery vehicle. 
As well as the thermoresponsive nature of OEGMA-based polymers the 
addition of a disulfide crosslinking within NPs allows for dual-stimuli-
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responsive drug delivery. Ulasan and co-workers developed a p(OEGMA-co-
vinyl pyrrolidone) NP system using a disulfide-based cross-linker by 
surfactant-free emulsion polymerisation.71 It was found that by using 
temperature as a trigger small molecular weight drug molecules could be 
released; then by the addition of dithiothreitol (DTT), to mimic cleavage of 
disulfide bond in vivo, larger drug molecules (PEG-alizarin dye as a model) 
could be released. This use of two stimuli for the controlled release of two 
different drugs offers an advantage for the delivery of large 
biomacromolecule drugs currently being developed (e.g. proteins, siRNA). The 
use of redox as a trigger for stimuli-responsive materials is further discussed 
below. 
1.4.2  Glutathione (reducing conditions) 
A further trigger used to good effect with stimuli-responsive material is the 
change in pH. A hallmark of tumour environment is the lowered extracellular 
pH caused by excess metabolic acids (CO2 and lactic acid),
72 the pH can drop 
below 6.5 down from pH 7.4 in normal tissue. This pH gradient continues 
downward upon entry to the cell as within the intracellular organelles the pH 
can drop to 5.5 (endosomes) and below this in the lysosomes. This drop of 
almost 2 pH units is the cause for many anti-cancer drugs to be ineffective 
against solid tumours.73 However, the local drop in pH can be taken 
advantage of to trigger a response from CSPs. In addition to the drop in pH, 
the intracellular concentration of glutathione, a thiol-containing tripeptide 
responsible for the cleavage of disulfide bonds, is much higher than 
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extracellular.74 Many groups have taken advantage of this fact and used it to 
their advantage in designing of drug delivery vehicles. 
One such strategy is to use the acidity to bring about disassembly of a 
nanoparticle assembly to release its cargo i.e. the drug of choice. This involves 
the cross-linking of a core of a micelle and allow it be susceptible to a 
reducing environment. The micelle allows for the encapsulation of drugs and 
dyes, for monitoring, into the inner area and once pH drops the release of the 
drug is contained within a local area.75,76 Although this is not the typical idea 
of a CSP it does show that by taking this idea of disassembly and using it for 
CSPs it could be improved with the additional shell and targeting.  
An advantage of using a CSP is shown by Guo et al whereby a CSP can be used 
to encompass a water insoluble drug.77 Their 10 step synthesis afforded a 
mPEG-SS-PBLG (poly(benzyl L-glutamate)) diblock polymer which was able to 
form nano-scale micelles in aqueous media. These micelles could be loaded 
with a hydrophobic drug (SN-38) at encapsulation efficiency (e.e.) of 73.5% at 
a content of 10 wt%. The disulfide bond was used to attach the PEG shell so 
as to allow for the shedding of the shell upon entry to an environment with 
reducing conditions. This was successful and the CSPs themselves showed no 
inherent cytotoxicity. Although there were signs that there was a slight 
release of the drug in a non-reducing environment over time, this would have 
to be remedied but initial results look promising for this type of sheddable 
shell CSP. 
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Similar work to this by Jiang and co-workers showed comparable results with 
a different pH responsive block copolymer, poly((PEG-MEMA)-co-(Boc-Cyst-
MMAm))-block-PEG.78 Using the pH cleavable disulfide bond the micelle 
loaded with paclitaxel (PTX) (e.e. > 90%, high-loading up to 35 wt%) could 
deliver extremely rapid release after exposure to an reducing environment 
and so improving the cytotoxicity of free PTX, Figure 7. 
 
Figure 7. In vitro cytotoxicity of PTX-loaded PEG-P-SS-HP1 micelles  (LC 9.9%, black bars) on 
HepG2 cells after 48h of incubation in comparison with empty micelles (left white bars) and 
free PTX (right gray bars). Data represent the mean and standard deviation of four 
independent experiments.
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To enhance what are promising signs of an anticancer drug delivery vehicle, 
Jiang et al are investigation the adaptation of their design to incorporate an 
active targeting ligand to benefit the possibilities of this as a suitable drug 
delivery vehicle. 
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The motif of a sheddable shell, similar to Guo and coworkers, upon response 
to a reducing environment is something that groups are beginning to further 
develop. Cui et al used the same type of PEG shell as Guo et al but this time 
attaching it to a silica NP core.79 The silica core allows for the accommodation 
of guests, such as drugs or dyes, and the PEG shell was attached via a disulfide 
bond which is cleavable in reducing conditions (i.e. glutathione (GSH) rich 
environment which occurs around solid tumours). The group showed that 
there was a rapid release of the dye upon contact with GSH compared with 
no GSH present. Cell cytotoxicity studies using a MTT assay showed no 
adverse effects of the use of these CSPs, although only one cell line was 
tested, Figure 8.  
 
Figure 8 Cell survival of MCF-7 cells incubated with different concentrations of MSNs-SS-
mPEG alone, Dye-loaded MSNs-SS- mPEG, MTX alone, and MTX-loaded MSNs-SS-mPEG 
nanoparticles after 24 h incubation.
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The group aims to push on from these results and carry out further testing 
using various types of human cancer cell lines and how different pore-sizes of 
the silica core affects the release patterns. 
Sheddable outer shells promote the intracellular delivery of hydrophobic 
drugs which, without this motif, find it problematic to be delivered to the 
internal areas of cells. This is also shown by Sun et al, whereby dextran-SS-
poly (caprolactone) was used to incorporate DOX within self-assembled 
micelle.80 The release of DOX was compared with micelles not containing the 
disulfide bond which allowed for the shedding of the hydrophilic outer shell 
and the results shown, Figure 9. 
 
Figure 9 Fluorescence images of macrophage RAW264.7 cells incubated for 4 h with DOX 
loaded Dex-SS-PCL micelles  (left) and DOX loaded Dex-PCL micelles (right). The DOX dosage 
was 12.5 μg/mL. Red: DOX fluorescence; Blue: cell nuclei stained by DAPI.
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 There is a marked increase in quantity of DOX present in cells when the 
release can be accelerated with the use of this sheddable shell compared to 
the standard micelle lacking in the disulfide bond. 
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All of these shell sheddable forms of drug delivery show promise as an 
efficient way of enhancing the treatment of cancers. However, as the in-vitro 
testing is only carried out on selected cell-lines it cannot be determined how 
well the targeting of these vehicles are. It can be theorised that they all could 
take advantage of the EPR effect as passive targeting, but, with an added 
active targeting ligand the potential could rise even further. 
1.5  Receptor Targeting 
Receptor targeting when used in combination with stimuli-responsive 
material can only improve upon the selectivity of drug delivery. As outlined 
previously targeting the folate receptor is just one way of exploiting the over 
expressed receptors common among certain cancers. Two such types of 
receptor targeting are outlined below.  
1.5.1  CD44 
One such receptor is the CD44 receptor which has been found to be 
overexpressed in certain cancers (breast, colon and ovarian).81,82 CD44 is a 
receptor of hyaluronic acid (HA) which is regarded as an excellent bio-inert 
material due to the immunoneutral, biocompatible and biodegradable nature 
of the material.83,84 It has been reported that HA-paclitaxel conjugates enter 
cells via receptor-mediated endocytosis.83 Previous work concentrated on 
using HA to form a prodrug by conjugating HA backbone directly to a drug 
molecule.85 
Jeong and co-workers used the idea of HA targeting of the CD44 receptor as a 
basis for their research. A CSP was synthesised with HA for targeting and a 
core of PLGA (HAbLG).86 Proton NMR was used to confirm the presence of the 
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HA as a hydrophilic shell covering the core of PLGA upon precipitation, with 
DOX incorporated in the core. HAbLG was found to have particle size of under 
200 nm which is favourable for consideration for drug targeting.87 To 
determine the efficiency of the targeting HCT-116 (a human colon carcinoma 
cell line88) was used as it is found to overexpress the CD44 receptor. It was 
shown that when the CD44 receptor was not blocked there was strong 
fluorescence from DOX within the cells showing successful entry via receptor 
mediated endocytosis. This was confirmed by blocking the receptor and 
exposing the cells the HAbLG-DOX once again. On this occasion the 
fluorescence was very small confirming the hypothesis of cell entry and 
successful intracellular administration of DOX. 
In the same vein as that of Jeong et al, Ki Young Choi and colleagues used the 
targeting of potential of HA to synthesise a theranostic device.89 This group 
had previously demonstrated that poly(ethylene glycol) (PEG)-conjugated 
hyaluronic acid nanoparticles (P-HA-NPs) upon systemic administration 
resulted in accumulation in tumour tissue.90,91 It was noted that these P-HA-
NPs accumulated not only due to the EPR effect like many other NPs but also 
because of the CD44 receptor targeting, as above. As previous work 
confirmed the effectiveness of this type of CSP as a delivery agent, this study 
was concerned with evaluating the prospect as a theranostic system. P-HA-NP 
was conjugated with Cy5.5 and loaded with IRT (a hydrophobic anticancer 
treatment). The resulting CSP was then administered to mice and the tumours 
monitored, Figure 10. 
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Figure 10 Representative colon images of AOM/DSS-induced orthotopic colon cancer 
models that were pre-treated or treated with saline, IRT or IRT-P-HA-NPs. Images acquired 
at 6 h after intravenous injection of Cy5.5-P-HA-NPs.  
 It was determined that the dye allowed for early stage detection of the colon 
cancer with the delivery of the drug causing a reduction on the size of the 
tumours. 
As colon cancer is very difficult to be detected with the miss rate being as high 
as 27 % for small, flat and depressed neoplasms92 which in turn can lead to 
further metastases;93 any improvement in aiding the treatment and detection 
is a positive step. 
1.5.2   Folate Receptor 
Folate targeting has garnered much attention after Kamen and Capdevila 
reported that folates entered cells via a receptor-mediated endocytic 
process.94 The vitamin folic acid displays extremely high affinity (KD ~10 
-10 M) 
for its cell surface-orientated receptor95 which is overexpressed in some 
forms of cancer.96 This makes it a more than suitable target to aim for when 
targeting tumour cells. It has already been shown that different types of 
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agents have been delivered to cells via this mechanism, from MRI agents 97, 
small molecule drugs98 and liposomes with entrapped drugs.99 With this 
process already been shown to work there should be no reason why this 
cannot be applied successfully to CSPs. 
Indeed, Zhao et al showed that with a PTX loaded folic acid modified PLGA-
PEG CSP, a higher cytotoxicity was achieved than when PTX was used 
alone.100 Upon intravenous administration of the CSPs to mice tumours 
showed signs of regression and improvement of animal survival, compared 
with that observed when Taxol® was used. Similar results were obtained by 
Ming Shen and co-workers when polymethacrylates (PMA)-grafted 
poly(amidoamine) (PAMAM) CSPs were used with folate-PEGylation.101 It was 
found that this type of CSP not only had enhanced targeting abilities due to 
the presence of the folate receptor and help from the EPR effect but also that 
the lower pH in intra-tumoral spaces stimulated the release of the drug 
molecule. This led to in-vivo results that showed strong inhibition of tumour 
growth, Figure 11.  
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Figure 11 Tumours after the 15th injection with PTX injection, FA-PEG-PMA-PAMAM-NPs (1 
mg/kg) and saline group (n=6).
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Recently two groups have shown the advantages of combining multiple active 
targeting on one type of particle. By conjugating both glucose and folic acid to 
gold nanoparticles the uptake of the NPs was increased by 3.9 fold and 12.7 
fold when compared with AuNPs with only the folate or glucose ligands 
respectively.102 A similar study also targeted the folate receptor and included 
an anti-EGFR (epidermal receptor growth factor) on a single AuNP core.103 The 
Au NPs were shown to be taken up to a high degree in cell types expressing 
one of the receptors and if both receptors were over-expressed the ability of 
the dual targeted NP system to be taken up was enhanced further. The use of 
two targeting ligands is clearly advantageous for targeting disease sites where 
more than one type of receptor is over-expressed; however careful 
consideration must be made when designing these multi-targeted NPs to 
ensure no off-site targeting would occur. 
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The examples above for receptor targeting outline how the increase in 
accumulation of CSPs in tumour tissue can increase the therapeutic value of 
drugs over the dose of the free drug and result in higher accumulation of 
CSPs. The encapsulation of a drug with the CSP not only allows for the 
improved targeting of the drug but, with the added extra of having stimuli-
responsive material within the CSP allows for site specific release of the drug 
and longer circulation times. 
1.6  Adoption of Nanoparticle Delivery Systems in the Clinic 
As shown above there has been a large amount of progress made in the 
design and synthesis of drug delivery systems however the take up within the 
clinic has not followed this ever increasing trajectory of development 
preclinically. The main type of delivery system that has been developed is 
based on polymeric particles and liposomes. Currently there are only six 
clinically approved nanoparticle-based cancer therapies currently on the 
market, Table 2; these include polymer formulations Genexol-PM and 
liposomal formulations such as Doxil and Myocet. 
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Table 2 Examples of Nanomedicines for cancer approved by FDA 
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Drug 
Product 
Active 
Ingredient 
Formulation 
type 
Treatment Area 
FDA 
approved 
date 
Doxil doxorubicin 
PEGylated 
liposome 
Ovarian/breast cancer 1995 
Abraxane Paclitaxel Nanospheres Various cancers 2005 
Myocet doxorubicin Liposome Breast cancer 
2000 (EU 
and 
Canada) 
DaunoXome Daunorubicin Liposome 
HIV-related Kaposi 
sarcoma 
1996 
Marqibo Vincristine Liposome 
Philadelphia 
chromosomenegative 
lymphoblastic 
leukemia 
2012 
Genexol-PM Paclitaxel 
Polymer 
micelle 
Breast cancer/small 
cell lung cancer 
Marketed 
in Europe 
 
Doxil was the first FDA approved nanodrug treatment for cancer (AIDS-related 
Kaposi’s sarcoma and metastatic ovarian and breast cancer). The treatment 
consists of unilamellar liposome with a PEG coating to allow shielding from 
the reticuloendothelial system and reduce clearance times, thus improving its 
pharmacokinetic profile.105 Following this the remaining five formulations 
have been introduced into the clinic with the Marqibo being last formulation 
to hit the market in 2012.  
 To date there are no stimuli-responsive or actively targeted nanocarriers 
currently approved by the FDA. There are however two currently in clinical 
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trials, ThermoDox®, a thermoresponsive liposome treatment, and BIND-014 
an actively targeted polymeric NP. 
ThermoDox® is a heat-sensitive liposome which is used to encapsulate 
doxorubicin and deliver it in a burst effect when the temperature is raised to 
a specific temperature. At this temperature the liposome rapidly changes its 
structure which allows the doxorubicin to escape.106 This treatment has 
reached phase 3 clinical trials and has shown efficacy against primary liver 
cancer.  
BIND-014 consists of a hydrophobic biodegradable core (consisting of PLA or 
PLGA) with a PEG shell. With the addition of a S,S-2-[3-[5-amino-1-
carboxypentyl]-ureido]-pentanedioic acid (ACUPA) ligand the NP system was 
capable of targeting the prostate-specific membrane antigen (PSMA).107 
PSMA is a clinically validated transmembrane receptor which is overexpressed 
on the surface of prostate cancer cells and in the neovasculature of nearly all 
non-prostate solid tumours.108 During the development of BIND-014 more 
than 100 different NP compositions were thoroughly investigated in order to 
ensure that the highest possible drug loading of docetaxel and most stable 
NPs were formulated, the outcome of this investigation is shown in Figure 12. 
After impressing in preclinical trials the formulation is currently in phase 2 
clinical trials. To date it has been shown that BIND-014 is well tolerated and 
the anti-tumour activity measured is meaningfully lower at lower dose than 
that for conventional docetaxel dosing.109  
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Figure 12 Range of formulation parameters and NP physicochemical properties evaluated 
during development of BIND-014, with optimized parameters and target properties 
indicated by the red dotted line.
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With the success these types of stimuli-responsive nanoparticle delivery 
systems are having in clinical trials it is hopefully only a short time until they 
are available for treatment. 
1.7  Conclusion 
It is hoped that the reader has been informed on some of the recent 
developments in the field of stimuli-responsive NPs and the development of 
NPs as drug delivery formulations. As to date there are only six approved 
nanoparticle delivery vehicles in the clinic104,110 there is still a long journey to 
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cover before NP drug delivery is common place. That said the promise of 
these CSPs as an effective and efficient delivery of anti-cancer drugs cannot 
be overlooked; with continued high quality research more and more of these 
NPs will find their place amongst a clinician’s arsenal for the fight against 
cancer. 
1.8  Project aims: 
This introduction has outlined the potential for polymer nanoparticles to be 
used as a targeted drug delivery vehicle to aid in cancer treatment. There has 
been progress made in the development of both stimuli responsive and 
receptor targeted NPs however very little work has been carried out in the 
combination of both into one formulation. Previous investigations have 
shown merit in both approaches for targeting nanoparticles to cancerous 
cells.  
1.8.1  Principal aims: 
The overall aim of this thesis was to develop a thermoresponsive polymer 
nanoparticle formulation that was capable of targeting cancer cells in vitro. 
The nanoparticle formulation was to contain a ‘hide-and-reveal’ motif 
designed to only reveal a folate targeting ligand upon heating the formulation 
beyond its transition temperature. The premise behind the ‘hide-and-reveal’ 
motif was to minimise off-site targeting by the folate ligand whilst maximising 
uptake within cancer cells which overexpress the folate receptor. To succeed 
in accomplishing this aim, the thesis is divided into the following experimental 
chapters: 
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Chapter 2: The design and synthesis of the polymers required for the 
assembly of the targeted nanoparticles. Selection of a suitable 
thermoresponsive polymer for in vitro testing and synthesis of polymers 
tagged with folate ligand for receptor targeting. 
Chapter 3: Development of a reproducible method for nanoparticle assembly.  
Chapter 4: Tuning the aggregation temperature of thermoresponsive 
nanoparticles. 
Chapter 5: Assessing the targeting capabilities of the thermoresponsive 
nanoparticle system in vitro. 
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2  Design and Synthesis of the Polymers for the Assembly of 
Targeted Nanoparticles  
 
2.1   Introduction 
Many possible reactions exist for the synthesis of polymers;14,111-114 each type 
capable of assembling multiple types of polymer with a wide variety of 
potential structural motifs.  
Ring-opening polymerisation (ROP); for which there are three main routes of 
initiation: radical, ionic (anionic or cationic) and metathesis, is one of the most 
documented polymerisation methods, with over 2,600 papers published in 
2015 alone,115 due to their simple set-up and ease of use. 
In this work anionic ROP was employed for the quick, controlled and 
reproducible assembly of polymers. The simplicity of the method, which 
requires only the presence of a catalyst, such as a tin14 or aluminium116 cation,  
and a nucleophilic initiator, which in this case was an alcohol, was a major 
factor in choosing this technique. For the remainder of this chapter anionic 
ROP will hereby be denoted by the abbreviation ROP. 
ROP has garnered much attention in recent years, with many groups 
attempting to dissect the intricate mechanism. Tin(II) 2-ethylhexanoate is a 
frequently used catalyst yet there still remains uncertainty as to its 
mechanism of action. One theory supports tin(II) coordinating with the 
initiator with the retention of the ethylhexanoate ligands (EH)117, whilst 
another suggests that the EH ligands are liberated upon coordination with 
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initiator.118 More recently, support for the coordination-insertion mechanism 
has been obtained.119 Using methanol as the reacting alcohol, two molecules 
of methanol were found to coordinate to Sn(OAc)2, as a model for Sn(EH)2, 
and the two ethylhexanoate moieties were found to be retained. The alcohol 
ligand is subsequently converted to an alkoxide which reacts with cyclic 
monomers via nucleophilic attack.  
A more complex set of reactions, when directly compared with ROP, free 
radical polymerisations necessitates highly controlled environments. The 
system is required to be completely void of air (oxygen) for the reaction to 
proceed. These types of polymerisations often require specialist equipment 
and make producing the desired polymers challenging.  
To overcome the aforementioned problems, new methods of polymerisation 
have been discovered that enable synthesis of polymers without the 
imposition of these strict conditions. One such type of polymerisation is Atom 
Transfer Radical Polymerisation (ATRP) which itself can be sub-categorised 
into a number of methods that are finding themselves common place 
amongst many polymer chemistry laboratories due to their flexibilities in 
terms of both monomer choice and catalysts used.120-124 One of these 
methods, which will feature heavily in this work is the activator generated by 
electron transfer (AGET) ATRP.  
AGET ATRP was first reported by the Matyjaszewski group in 2005.125 This 
technique uses relatively air stable complexes, such as copper (II), with the 
active catalyst being generated in situ. The general mechanism is shown in 
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Scheme 1; the copper(II) catalyst is reduced by tin (II) 2-ethylhexanoate to Cu 
(I), the Cu (I) is then used to form the initiator radical which reacts with the 
methacrylate monomers in solution via a step-wise process to form the 
desired polymer. The degree of polymerisation can be easily controlled by 
altering the monomer to initiator ratio as well as the duration of the reaction. 
The advantage of this type of polymerisation is the increased tolerability of 
the catalysts to air, allowing for small amounts of oxygen to be present 
without interfering with the reaction progression, either by affecting the 
catalyst or reaction intermediates.  
  
Scheme 1 AGET ATRP schematic. The Cu (II) is reduced by Sn(EH)2 to produce the active 
catalyst Cu (I), this produces the initiator radical (P) which reacts with the 
acrylate/methacrylate monomers (M) to form the random block copolymer. To form a 
more ordered copolymer the monomers can be added in batches.  
The polymers used for the targeted nanoparticle assembly were synthesised 
using both ROP and AGET ATRP as polymerisation techniques. Firstly, ROP 
was utilised to synthesise the hydrophobic core, comprising either a 
poly(lactide-co-glycolide) (PLGA) or polylactide (PLA). PL(G)A was chosen as a 
core material due to its attractive properties for clinical use, such as 
biodegradability and biocompatibility, its well described formulation methods 
for drug encapsulation and its approval for use by the FDA and EMA.126 The 
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introduction of hydrophobicity also allows for the complete encapsulation of 
poorly soluble drug molecules in the future allowing for PL(G)As use as a drug 
delivery vehicle.  
The PL(G)A core was further functionalised with a hydrophilic 
thermoresponsive shell, synthesised via AGET ATRP, capable of forming stable 
self-assembled nanoparticles (NPs). Within this thermoresponsive NP a ‘hide-
and-reveal’ motif was included with the intention of enhancing targeting of 
the NPs to cancerous tumour cells; accordingly, a folate tagged PLA-PEG 
polymer was included within the NP. The folate tag was designed to be 
“visible” to the cell receptor only upon raising the temperature of the 
tumour/cell environment beyond the transition temperature of the 
thermoresponsive shell, as shown in Figure 13.  
 
Figure 13 Design of the "hide-and-reveal" folate targeted thermoresponsive nanoparticles 
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2.2   Methods 
For full details of all materials and equipment used consult Chapter 7. All GPC 
was carried out in chloroform and NMR was carried out in deuterated 
chloroform unless otherwise stated. 
2.2.1  O-(2 -Bromoisobutyryl)tetraethylene glycol (ROP initiator) synthesis 
Tetraethylene glycol (10.0 g, 51.5 mmol) was dried by azeotropic distillation 
of its solution in toluene (100 mL) twice then dissolved in CH2Cl2 (100 mL). 
NaHCO3 (10 g, 119 mmol) was added followed by drop-wise addition of 2-
bromoisobutyryl bromide (13.0 g, 7.0 mL, 56.6 mmol). The resulting 
suspension was stirred under N2 overnight after which complete consumption 
of the acyl bromide was confirmed by TLC. Solids were removed by filtration 
and volatiles removed in vacuo. The resulting oil was purified by flash column 
chromatography (silica gel, 60 Å, 35–70 μm) with EtOAc as the eluent  to yield 
O-(2 -bromoisobutyryl)tetraethylene glycol (1) as a clear viscous liquid. 
Yield: 2.2 g (12.5 %)  
1H NMR – δ / ppm (d6-DMSO): 1.90 (s, 6H, CH3), 3.40-3.70 (m, 14H, O-CH2-
CH2), 4.25 (s, OH). 
2.2.2  PLGA Synthesis 
2.2.2.1  50:50 PLGA 
2.2.2.1.1  Sn(II) catalysed ROP 
Glycolide (2.42 g, 21 mmol), D,L-lactide (3.0 g, 21 mmol) and initiator (1) (0.18 
mg, 0.52 mmol) were added together with a stirrer bar to a round bottom 
flask. The mixture was stirred under nitrogen for 10 min at 50 °C before 
temperature was raised to 130 °C, after which tin (II) ethylhexanoate (42 mg, 
0.1 mmol) was added and stirred overnight. The product formed was 
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dissolved in CH2Cl2 prior to being precipitated three times in cold hexane. The 
resulting precipitate was dissolved in CH2Cl2 and recovered in vacuo. Yield: 
2.08 g. (38 %) 
GPC: Mn 2307 Da, Đ 2.33 
1H NMR – δ / ppm (CDCl3): 1.25-2.0 (m, 87.53H, lactide CH3), 2.25 (s, 3H, CH3), 
3.47-3.80 (m, 6.95H CH2CH2O), 4.58-4.98 (m, 86.94H, glycolide CH2), 5.03-5.39 
(m, 38.55H, lactide CH). 
2.2.2.1.2  1,5,7-Triazabicyclo[4.4.0]dec-5-ene (TBD) catalysed ROP 
Glycolide (0.5 g, 4.3 mmol), D,L-lactide (0.62 g, 4.3 mmol) and initiator (1) (60 
mg, 0.175 mmol) were dissolved in CH2Cl2 (10 mL) in a round bottom flask. 
The mixture was stirred under nitrogen for 10 min at 50 °C to aid dissolution, 
after which TBD (10 mg, 0.07 mmol) in CH2Cl2 (1.5 mL) was added and stirred 
for 0.5 h. The reaction solution was precipitated three times in cold hexane. 
The resulting precipitate was dissolved in CH2Cl2 and recovered in vacuo. 
Yield: 0.8 g (71 %). 
GPC: Mn 1100 Da, Đ 2.31 
1H NMR – δ / ppm (d6-DMSO): 1.33-1.57 (d, 8.1H, lactide CH3), 2.5 (s, 2.9H, 
CH3), 3.08-3.59 (br s, 18.5H CH2CH2O), 5.05 (s, 1H, glycolide CH2), 5.45 (q, 
2.56H, lactide CH). 
2.2.2.2  65:35 PLGA 
Glycolide (3.25 g, 28 mmol), D,L-lactide (7.49 g, 52 mmol) and initiator (1) (273 
mg, 0.8 mmol) were added together with a stirrer bar to a round bottom 
flask. The mixture was stirred under nitrogen for 10 min at 50 °C before the 
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temperature was raised to 130 °C  after which tin (II) ethylhexanoate (65 mg, 
0.16 mmol) was added and stirred for 30 minutes. The product formed was 
dissolved in CH2Cl2 prior to being precipitated three times in cold hexane. The 
resulting precipitate was dissolved in CH2Cl2 and recovered in vacuo. Yield: 
9.15 g (85 %). 
GPC: Mn 18100 Da, Đ 1.56 
1H NMR – δ / ppm (CDCl3): 1.46-1.68 (m, 156.45H, lactide CH3), 1.95 (s, 3H, 
CH3), 3.62-3.81 (m, 7.12H CH2CH2O), 4.61-4.97 (m, 63.34H, glycolide CH2), 
5.11-5.31 (m, 46.24H, lactide CH). 
Mn, NMR: 7300 Da 
Lactide:glycolide 62:38 (by 1H NMR) 
2.2.2.3  75:25 PLGA 
Glycolide (2.15 g, 18.5 mmol) and D,L-lactide (80 g, 55.5 mmol) were 
combined with 1 (273 mg, 0.8 mmol) in a round-bottomed flask, the 
remainder of reaction was repeated as for 65:35 PLGA-Br. Yield: 9.10 g (90 %). 
GPC: Mn 19500 Da, Đ 1.89 
1H NMR – δ / ppm (CDCl3): 1.26-1.80 (m, 201.3H, lactide CH3), 1.95 (s, 3H, 
CH3), 3.56-3.83 (m, 5.18H CH2CH2O), 4.56-5.01 (m, 44.4H, glycolide CH2), 5.09-
5.50 (m, 67.81H, lactide CH). 
Mn, NMR: 12700 Da 
Lactide:glycolide 74:26 (by 1H NMR) 
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2.2.3  PLA synthesis 
2.2.3.1  Sn (II) catalysed 
Initiator (1) (500 mg, 1.45 mmol) and D,L-lactide (30.0 g, 0.2 mol) were added 
to a RBF together with a stir bar and heated to melt (130 °C) under nitrogen 
for 30 min. Tin (II) ethylhexanoate (200 mg, 0.49 mmol) was added using a 
syringe. The reaction was left to stir under nitrogen for 1 h. The product 
formed was dissolved in CH2Cl2 prior to being precipitated three times in cold 
hexane. The resulting precipitate was dissolved in CH2Cl2 and recovered in 
vacuo. Yield: 29.5 g (98 %)  
GPC: Mn 13300 Da, Ð 1.77 
1H NMR – δ / ppm (CDCl3): 1.50-1.66 (m, 472.2H, lactide CH3), 1.95 (s, 3H, 
CH3), 3.59-3.82 (m, 6.4H CH2CH2O), 5.12-5.30 (m, 139.55H, lactide CH). 
Mn, NMR: 15600 Da 
 
2.2.3.2  TBD catalysed 
Compound 1 (1.7 g, 4.88 mmol) and D,L-lactide (34.0 g, 0.23 mol) were 
dissolved in dry CH2Cl2 (160 mL). TBD (680 mg, 4.88 mmol) was dissolved in 10 
mL CH2Cl2 and added upon complete dissolution of monomers and left to stir 
for 30 minutes to ensure complete polymerisation. The reaction mixture was 
precipitated into cold hexane twice and polymer recovered in vacuo. Yield 
33.9 g (99 %). 
GPC: Mn 16100 Da, Ð 1.87 
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1H NMR – δ / ppm (CDCl3): 1.42-1.74 (m, 757H, lactide CH3), 1.95 (s, 3H, CH3), 
3.62-3.82 (m, 2.33H CH2CH2O), 5.11-5.30 (m, 246.77H, lactide CH). 
Mn, NMR: 26600 Da 
2.2.4  Poly(lactide-co-glycolide)-block-((polypropylene glycol 
methacrylate)-stat-(oligo(ethylene glycol) methacrylate) (PLGA-b-
(PPGMA-stat-OEGMA)) 
To a round-bottom flask PLGA-Br (0.1 mmol), PMDTA (21 μL, 0.1 mmol) and 
CuBr2 (23 mg, 0.1 mmol) were added. To the mixture, varying amounts of the 
two co-monomers, PPGMA375 and OEGMA475, were added in order to give 
polymers with different thermoresponsive properties. All the materials were 
dissolved in 15 mL of 2-butanone. The mixture was degassed by flushing with 
Ar or N2 and stirred for 1 h. Tin (II) 2-ethyl-hexanoate (0.1 mmol) was added 
as the AGET reducing agent under Ar. The reaction was heated to 60 °C and 
stirred for 3-6 h (until 60-70% monomer conversion). The polymerization was 
stopped by opening the flask and exposing the contents to air. The reaction 
mixture was precipitated three times into an excess of hexane: diethyl ether 
(1:1) mixture. The precipitate was then dissolved with CH2Cl2 and passed 
through an aluminium oxide column. The resulting co-polymer was obtained 
by evaporating to dryness in vacuo. 
1H NMR – δ / ppm (CDCl3): (P1) 1.50-1.68 (m, 14.19H, lactide CH3), 3.40 (s, 3H, 
OEGMA CH3), 3.86-4.20 (m, 4.87H, OEGMA CH2, PPGMA CH), 4.63-4.98 (m, 
4.8H, glycolide CH2), 5.11-5.39 (m, 5.02H, lactide CH). 
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(P2): 1.50-1.68 (m, 10.44H, lactide CH3), 3.40 (s, 3H, OEGMA CH3), 3.86-4.20 
(m, 533H, OEGMA CH2, PPGMA CH), 4.63-4.98 (m, 5.4H, glycolide CH2), 5.11-
5.39 (m, 3.99H, lactide CH). 
(P3): 1.50-1.68 (m, 12.17H, lactide CH3), 3.40 (s, 3H, OEGMA CH3), 3.86-4.20 
(m, 2.4H, OEGMA CH2, PPGMA CH), 4.63-4.98 (m, 3.98H, glycolide CH2), 5.11-
5.39 (m, 3.91H, lactide CH). 
(P4): 1.50-1.68 (m, 9.92H, lactide CH3), 3.40 (s, 3H, OEGMA CH3), 3.86-4.20 (m, 
2.6H, OEGMA CH2, PPGMA CH), 4.63-4.98 (m, 4.58H, glycolide CH2), 5.11-5.39 
(m, 3.25H, lactide CH). 
 (P5): 1.5-1.64 (m, 18.83H, lactide CH3), 3.40 (s, 3H, OEGMA CH3), 3.87-4.20 
(m, 3.65H, OEGMA CH2, PPGMA CH), 4.63-4.98 (m, 5.16H, glycolide CH2), 
5.11-5.39 (m, 6.04H, lactide CH). 
 
2.2.5  Poly(lactide)-block-((2-methoxyethoxy)ethylmethacrylate)-stat-
(oligo(ethylene glycol) methacrylate) (PLA-PEGMA) 
To a round bottom flask, a poly(lactide) macroinitiator (0.1 mmol), PMDTA (21 
μL, 0.1 mmol) and CuBr2 (23 mg, 0.1 mmol) were added. To the mixture 
varying amounts of the two co-monomers, DEGMA and OEGMA475, were used 
to give polymers with different properties. All the materials were dissolved in 
15 mL of 2-butanone. The mixture was degassed by 3 cycles of freeze-pump-
thaw prior to being backfilled with Ar. Tin (II) 2-ethyl hexanoate (40.5 mg, 0.1 
mmol) was added as the AGET reducing agent under Ar. The reaction was 
heated to 60 °C and stirred for 3 – 6 h to achieve 60-70% monomer 
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conversion. The polymerisation was stopped by opening the flask and 
exposing the contents to air. The reaction mixture was precipitated three 
times into an excess of cold hexane. The precipitate was then dissolved with 
CH2Cl2 and passed through an aluminium oxide column to remove copper. 
The resulting co-polymer was obtained by evaporating to dryness in vacuo. 1H 
NMR – δ / ppm (CDCl3): (P6) 1.46-1.69 (m, 11.07H, lactide CH3), 3.42 (s, 3H, 
D/OEGMA CH3), 3.49-4.29 (m, 8H, D/OEGMA CH2), 5.08-5.30 (m, 3.6H, lactide 
CH). 
(P7): 1.46-1.69 (m, 10.34H, lactide CH3), 3.42 (s, 3H, D/OEGMA CH3), 3.49-4.29 
(m, 8.58H, D/OEGMA CH2), 5.08-5.30 (m, 2.98H, lactide CH). 
(P8): 1.46-1.69 (m, 11.18H, lactide CH3), 3.42 (s, 3H, D/OEGMA CH3), 3.49-4.29 
(m, 10.08H, D/OEGMA CH2), 5.08-5.30 (m, 3.5H, lactide CH). 
(P9): 1.46-1.69 (m, 10.8H, lactide CH3), 3.42 (m, 3H, D/OEGMA CH3), 3.49-4.29 
(m, 12.3H, D/OEGMA CH2), 5.08-5.30 (m, 3.35H, lactide CH) 
(P10): 1.46-1.69 (m, 12.38H, lactide CH3), 3.42 (m, 3H, D/OEGMA CH3), 3.49-
4.29 (m, 17.42H, D/OEGMA CH2), 5.08-5.30 (m, 3.97H, lactide CH) 
(P11): 1.46-1.69 (m, 12.16H, lactide CH3), 3.42 (m, 3H, D/OEGMA CH3), 3.49-
4.29 (m, 21.9H, D/OEGMA CH2), 5.08-5.30 (m, 3.88H, lactide CH) 
2.2.6  Fluorescent PLA-PEGMA synthesis 
To a round bottom flask, a poly(lactide) macroinitiator (1 mmol), PMDTA (210 
μL, 1 mmol), CuBr2 (230 mg, 1 mmol) and rhodamine methacrylate (25.6 mg, 
0.0375 mmol) were added. To the mixture varying amounts of the two co-
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monomers, DEGMA and OEGMA475, were used to give polymers with different 
properties. All the materials were dissolved in 25 mL of 2-butanone. The 
mixture was degassed by 3 cycles of freeze-pump-thaw prior to being 
backfilled with Ar. Tin (II) 2-ethyl hexanoate (405 mg, 1 mmol) was added as 
the AGET reducing agent under Ar. The reaction was heated to 60 °C and 
stirred for 3 – 6 h to achieve 60-70% monomer conversion. The 
polymerisation was stopped by opening the flask and exposing the contents 
to air. The reaction mixture was precipitated three times into an excess of 
cold hexane. The precipitate was then dissolved with CH2Cl2 and passed 
through an aluminium oxide column to remove copper. The resulting co-
polymer was obtained by evaporating to dryness in vacuo. 
(P12): 1.51-1.64 (m, 8.24H, lactide CH3), 3.42 (m, 3H, D/OEGMA CH3), 3.49-
4.29 (m, 9.22H, D/OEGMA CH2), 5.08-5.30 (m, 2.68H, lactide CH) 
(P13): 1.51-1.64 (m, 17.78H, lactide CH3), 3.42 (m, 3H, D/OEGMA CH3), 3.49-
4.29 (m, 11H, D/OEGMA CH2), 5.08-5.30 (m, 5.63H, lactide CH) 
2.2.7  2-(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-
yl)methyl)amino)benzoyl)-5-(prop-2-yn-1-yl)glutamine (Propargyl folate) 
synthesis 
Folic acid (1 g, 2.2 mmol), N-hydroxysuccinimide (260 mg, 2.5 mmol) was 
dissolved in 10 mL anhydrous DMF and cooled to 0 °C before adding 1-ethyl-
3-(3-dimethylaminopropyl)carbodiimide (440 mg, 2.5 mmol). Reaction 
mixture was left to stir for 30 minutes until white precipitate had formed. 
Propargyl amine (124 mg, 22.5 mmol) in 5 mL anhydrous DMF was added and 
the reaction warmed to room temperature. After 24 h the product was 
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precipitated in 100 mL water. Precipitate was filtered and washed with 
acetone before drying. Yield 781 mg (81.7%, orange solid) 
MS (m/z): [M+H]+ 479.1779 
[M+K]+ 517.1387 
 
Figure 14 HPLC chromatogram of propargyl folate. Observed Peak shows β-substitution 
(main peak) and α-substitution (shoulder of peak). Sample prepared in DMSO diluted with 
water. HPLC method: 10%-20% MeCN over 17 minutes, UV detection at 363 nm.  
2.2.8   2-(4-(((2-amino-4-oxo-3,4-dihydropteridin-6-
yl)methyl)amino)benzoyl)-5-diazoglutamine (Azido-folate) synthesis 
Folic acid (250 mg, 0.56 mmol) 2-(2-(2-azidoethoxy)ethoxy ethanol (90 µL, 
0.588 mmol), DCC (231 mg, 1.12 mmol) and DMAP (1.7 mg, 0.014 mmol,) 
were dissolved in 25 mL DMSO under nitrogen. The reaction was stirred 
under nitrogen for 30 minutes until complete dissolution of the folic acid. The 
reaction proceeded at room temperature for 18 h under stirring. Upon 
completion the product was precipitated into pure water and product was 
recovered by centrifugation and freeze-drying. Yield: 215 mg (64.2%, pale 
yellow solid) 
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MS (m/z): [M+H]+ 599.2058 
 
Figure 15 HPLC chromatogram of azido-folate. Observed Peak shows β-substitution (main 
peak) and α-substitution (shoulder of peak). Sample prepared in DMSO diluted with water. 
HPLC method: 10%-20% MeCN over 17 minutes, UV detection at 363 nm.  
2.2.9   PLA-PEG synthesis 
2.2.9.1  PEG450: 
D,L-Lactide (5.18 g, 36 mmol) and O-(2-aminoethyl)-O′-(2-
azidoethyl)nonaethylene glycol (95 mg, 0.18 mmol) were heated to 120 °C 
under nitrogen then tin (II) ethylhexanoate (50 mg, 0.12 mmol) was added. 
The reaction was left to stir for 1 h before cooling. The product formed was 
dissolved in CH2Cl2 prior to being precipitated three times in cold hexane. The 
resulting precipitate was dissolved in CH2Cl2 and recovered in vacuo. Yield: 
4.78 g (90 %) 
GPC: Mn 19000 Da, Ð 1.51 
2.2.9.2  PEG3k: 
D,L-Lactide (1.44 g, 10 mmol) and amino-PEG3k-alkyne (67 mg, 0.02 mmol) 
were heated to 120 °C under nitrogen then tin (II) ethylhexanoate (2.5 mg, 
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0.006 mmol) was added. The reaction was left to stir for 1 h before cooling. 
The product formed was dissolved in CH2Cl2 prior to being precipitated three 
times in cold hexane. The resulting precipitate was dissolved in CH2Cl2 and 
recovered in vacuo. Yield: 930 mg (64 %). 
GPC: Mn 19100 Da, Ð 1.89  
2.2.9.3  PEG10k: 
D,L-Lactide (972 mg, 6.75 mmol) and amino-PEG10k-alkyne (450 mg, 0.048 
mmol) were heated to 120 °C under nitrogen then tin (II) ethylhexanoate (10 
mg, 0.024 mmol) was added. The reaction was left to stir for 1 h before 
cooling. The product formed was dissolved in CH2Cl2 prior to being 
precipitated three times in cold hexane. The resulting precipitate was 
dissolved in CH2Cl2 and recovered in vacuo. Yield: 830 mg (58 %). 
GPC: Mn 20400 Da, Đ 1.86 
2.2.10  PLA-PEG-Folate synthesis 
PLA-PEG-N3 (0.5 g, 0.026 mmol), propargyl folate (20 mg, 0.039 mmol), 
copper (I) bromide (5 mg, 0.03 mmol) and 2-2’-bipyridyl (6.2 mg, 0.04 mmol)  
were dissolved in 4.5 mL dry dimethylacetamide (DMAc) and stirred under 
argon for 30 min. The reaction was stirred for 3 days at room temperature 
prior to dilution with 10 mL DMAc and precipitated into ice cold diethyl ether. 
The precipitate was obtained by centrifugation, dissolved in minimal CH2Cl2 
and passed through an alumina plug to remove excess copper. 
Yield: 429 mg (86 %). 
GPC: Mn 19400 Da, Đ 1.19. 
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2.3   Results 
The synthesis of the polymers required to form the targeted nanoparticles 
occurred in three steps 
1. PLGA/PLA synthesis 
2. Thermoresponsive polymer synthesis using the PLGA/PLA macro-
initiator 
3. Folate tagged polymer synthesis 
Each step in turn of the synthesis will be discussed in detail below. 
2.3.1  Step one: PLGA/PLA synthesis 
2.3.1.1  PLGA synthesis 
PLGA was to be used to form the hydrophobic block of the thermoresponsive 
copolymer and as the following step employed atom transfer radical 
polymerisation (ATRP), PLGA would need to be synthesised with a bromine 
end group. 
The terminal bromine atom was incorporated into PLGA using a bromine 
containing initiator O-(2-bromoisobutyryl)tetraethylene glycol (1) for the ROP 
of both lactide and glycolide monomers, Scheme 2. 
 
Scheme 2 Synthetic scheme for the synthesis of O-(2-bromoisobutyryl)tetraethylene glycol. 
Reaction conditions: NaHCO3, 0°C – RT, overnight.  
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The bromide-containing initiator was synthesised by the nucleophilic 
substitution of tetraethylene glycol with 2-bromoisobutyryl bromide, 
achieving a final yield of 2.2 g (12.5 %) to be used in the ROP of lactide and 
glycolide, Scheme 2. The low yield can be attributed to the limited selectivity 
between reactants; the tetraethylene glycol has two terminal nucleophilic 
hydroxyl groups capable of reacting with the carbonyl of the acyl bromide and 
thus both mono- and di-substituted tetraethylene glycol are obtained. As only 
the mono-substituted initiator is required for the ROP, the di-substituted 
product (plus any unreacted materials) was removed by silica column 
chromatography.   
Initial research aims required synthesis of polymers containing 50:50 PLGA 
(lactide-glycolide) as previous work within the group proposed these 
polymers as a good foundation for a thermoresponsive polymer NP.127  
The synthesis of the 50:50 (lactide-glycolide) NPs was carried out under 
solvent free conditions with tin (II) chosen as an appropriate catalyst for the 
ROP, Scheme 3. However, initial attempts yielded polymers with both high 
polydispersity (Đ ≈3) and low Mn <5000 Da, indicating that there was scope 
for method optimisation. The method was further investigated in order to 
yield more defined polymers for ATRP, i.e. with Mn 10-20 kDa and Đ < 2.
127   
 
Scheme 3 Synthetic scheme for PLGA formation via ROP 
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The first approach was to introduce an alternative catalyst. Recent advances 
in organo-catalyst research led to the development of metal free catalysed 
ring opening polymerisations which offered an alternative to the more 
commonly reported inorganic catalysed ROP.128 
Three organic catalysts were chosen for this optimisation reaction; 1,5,7-
Triazabicyclo[4.4.0]dec-5-ene (TBD) (3),129 1,8-Diazabicyclo[5.4.0]undec-7-ene 
(DBU) (4),130 and 1-(3,5-bis(trifluoromethyl)phenyl)-3-cyclohexylthiourea 
(5)131,132 with dimethylaminopyridine as co-catalyst, Figure 16.  
 
Figure 16 Organic catalysts used for ROP. 3: TBD. 4: DBU. 5: 1-(3,5-
bis(trifluoromethyl)phenyl)-3-cyclohexylthiourea  
These catalysts have previously been used for the ROP of cyclic esters,128 
including lactide, however not for the co-ROP of lactide and glycolide to form 
PLGA. The ROP with the organo-catalysts was investigated in both the melt 
and solution phases, but unfortunately none of the catalysts were found to 
produce PLGA with the desired Mn or polydispersity, affording an average Mn  
of 1000 – 3000 Da; significantly less than the Mn of the PLGA formed using the 
previous tin (II) catalyst. This can be explained by a possible lack of reactivity 
with the chosen co-monomers. Due to the lack of reactivity and inherent 
insolubility of the polymers produced, the decision to decrease the quantity 
of glycolide present in the PLGA was taken. Further optimisation of the 
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reaction was carried out by altering the ratio of lactide to glycolide to 
generate polymers with both greater Mn and solubility.  
2.3.1.1.1  65:35 and 75:25 PLGA synthesis 
As a proof of concept, initial studies to determine the effect of monomer ratio 
was carried out using only the 75:25 PLGA synthesis.  
ROP on a 500 mg scale yielded approximately 325 mg of polymer after 2 h, 
however the calculated Mn for the resulting polymer was less than 1000 Da 
with a Ð of 2. The large Đ and low Mn was thought to be due to inefficient 
stirring of the monomers. As the polymer formed, the melt became overly 
viscous, decreasing the likelihood that the monomers were homogenously 
mixed. With a lack of stirring the polymer that formed was not able to come 
in contact with all the monomer present thus the low Mn observed. 
To overcome the problem with mixing, the reaction was scaled up (2.5 g), 
increasing the final volume of the system, this allows for more efficient mixing 
using a stirrer bar ensuring that the melted monomers were able to form a 
homogenous mix with the initiator and catalyst. Under these conditions the 
catalyst was found to be well mixed with the monomers and initiator which 
enabled the reaction to proceed more efficiently, yielding a 75:25 PLGA 
polymer with Mn of 8 kDa. The Đ of this polymer was 2.7 however following 
purification it was possible to remove the lower molecular mass fractions. As 
this was the largest Mn achieved, it was thought that using a larger reaction 
scale would enhance the outcome of the polymerisation and potentially lead 
to the formation of a polymer with the desired properties, i.e. Mn, closer to 
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10-20 kDa and Đ , 2. The increased reaction scale also provided the additional 
benefit of allowing a large quantity of PLGA to be synthesised in one pot, 
ensuring batch-to-batch variability was minimised for consistency during 
further polymerisations. 
To validate the robustness of the synthetic protocol the reaction was scaled 
up further to both 10 g and 30 g for 65:35 and 75:25 PLGA. Table 1 reports 
the observed Mn and Đ values calculated from the 75:25 polymerisation 
reactions, however, the values reported for 10 g and 30 g are representative 
of the values also obtained in the polymerisation of 65:35 PLGA.  
Table 3 Properties of 75:25 PLGA-Br achieved from reaction scale-up 
Reaction scale (g) Reaction time (h) Mn (Da) Ð 
0.5 2 920 2.01 
2.5 2 8300 2.76 
10 0.5 13900 1.49 
30 0.5 19500 1.89 
     
The scale up to 10 g and 30 g generated PLGA in sufficient Mn and Ð (10 - 20 
kDa and Đ < 2). This method was therefore progressed through to subsequent 
steps in the synthesis of the thermoresponsive polymers. 
As demonstrated above, the synthesis of a reproducible PLGA proved to be 
very challenging both in terms of time and yields. It was not until larger scale 
reactions were implemented and reduced quantities of glycolide were used 
that PLGA of desired quality was obtained. Thus, it was thought that removing 
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glycolide as a contributing co-monomer could potentially enhance the 
reaction even further. The following section reports synthesis of a polylactide 
(PLA) homopolymer.  
 
2.3.1.2  The loss of glycolide: PLA synthesis 
The omission of glycolide was considered to provide a two-fold advantage: 
firstly, it would alleviate any concern over ensuring the ratio of glycolide to 
lactide remained consistent batch-to-batch. Secondly, by only using lactide as 
the monomer more scope was afforded to the type of catalysts that could be 
used to synthesise the polymer. Both inorganic catalysts, such as Sn2+, and 
organocatalysts, such as TBD and DBU, have been shown to polymerise 
lactide effectively. Initially both Sn2+ and TBD (3) were re-evaluated as 
suitable catalysts for the synthesis of PLA, to determine which method 
produced PLA of the highest quality. NMR scale reactions showed 3 was a 
suitable catalyst affording PLA with a Mn of 15 kDa and Đ of 1.7 following a 5 
min reaction time. Sn2+ was investigated also to determine if an improvement 
in the Đ could be achieved. Using the conditions mentioned above for the 
synthesis of PLGA, this method was found to produce PLA with a Mn and Đ 
similar to those formed when 3 was used. Both methods were found to be 
scalable, up to 30 g tested, however, there was a slight increase in the 
observed polydispersity (from 1.5 to 1.7) when TBD was used. Thus, both TBD 
and Sn2+ were validated as viable catalysts for PLA synthesis.  
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With the confirmation that both 65:35 and 75:25 PLGA could be synthesised 
using a Sn2+ catalyst and that PLA could be synthesised with ease using either 
Sn2+ or 3, the foundation was provided for the synthesis of the block 
copolymers that would make up the thermoresponsive shell of the NPs.   
 
2.3.2  Step two: Thermoresponsive polymer synthesis 
Polymerisation from the formed PLGA macro-initiator was achieved activator 
generated by electron transfer atom transfer radical polymerisation (AGET 
ATRP). 
Poly(1-hydroxypropan-2-yl) methacrylate (PPGMA) and poly(2-methoxyethyl) 
methacrylate (OEGMA) were used to impart thermoresponsive properties to 
the polymer, as shown in Figure 17. These monomers were chosen as they 
had previously been shown to produce thermoresponsive polymers with a 
variable transition temperature (Tt) of 31 – 84 °C dependent on the monomer 
ratio.127 
 
Figure 17 OEGMA475 and PPGMA375 monomers used for the synthesis of thermoresponsive 
polymers from PLGA 
By varying the ratio of these two monomers the amphiphilicity of the 
resulting polymer can be controlled, thus enabling fine tuning of the Tt; the 
more hydrophilic the outer shell of the NP the higher the Tt and vice versa.  
 
73 
Design and Synthesis of the Polymers for the Assembly of Targeted 
Nanoparticles 
OEGMA is the more hydrophilic monomer, containing nine ethylene glycol 
repeat units and thus presents more opportunity to hydrogen bond to water 
in solution. The greater the number of sites capable of hydrogen bonding to 
water the larger the amount of energy (by heating) that needs to be put into 
the system to break these hydrogen bonds and bring about the phase 
separation into polymer rich and polymer poor phases. As phase separation 
occurs there is a loss of colloidal stability when these thermoresponsive 
polymers are on the corona of nanoparticles.   
 
Scheme 4 Reaction scheme for the synthesis of PLGA-b-P((PPGMA)-stat-(OEGMA)) by AGET 
ATRP 
A small library of thermoresponsive PLGA-b-P((PPGMA)-stat-(OEGMA)) 
polymers was synthesised as shown in Table 4. Each of the polymers P1-P5 
were synthesised using both the 65:35 and 75:25 PLGA macro-initiator, 
Scheme 4.  
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Table 4 Feed ratio of monomers for the synthesis of PPGMA-OEGMA copolymers 
Polymer PPGMA:OEGMA PPGMA (mmol) OEGMA (mmol) 
P1 3:1 5.63 1.87 
P2 2:1 5 2.5 
P3 1:1 3.75 3.75 
P4 3:2 4.5 3 
P5 4:1 6 1.5 
   
 Synthesis was carried out on a 0.1 mmol scale (initiator) with 1:1:75 
[Ini.]:[cat.]:[monomer]. It was found that the average yield of each polymer 
was between 1.3-1.5 g with similar Mn and polydispersity values recorded. 
The mass analysis for each polymer synthesised was consistent (except for 
P5a and P5b, for which a different batch of PLGA with higher Mn was used) 
and therefore the Đ was found to be decreased for each (< 1.5). The data is in 
agreement with those figures previously published for similar polymers.127 
 
75 
Design and Synthesis of the Polymers for the Assembly of Targeted 
Nanoparticles 
Table 5 GPC results for copolymer synthesis (*Mn is larger for these two results due to a 
different batch of PLGA-Br which had a larger Mn itself.) 
Polymer Mn (kDa, GPC) Ð 
65:35 core 
P1a 21.0 1.35 
P2a 17.9 1.44 
P3a 18.3 1.39 
P4a 15.5 1.49 
P5a 37.0* 1.28 
75:25 core 
P1b 21.0 1.30 
P2b 19.3 1.31 
P3b 18.7 1.33 
P4b 19.3 1.31 
P5b 40.1* 1.36 
   
Upon completion of this library of polymers, NPs were assembled and tested 
for their thermoresponsive properties.  
2.3.2.1  Thermoresponsive properties of P1-P5 
For the NPs to progress through to in vitro testing a Tt of 30 – 35 °C was 
required. Maintaining this temperature would ensure the NPs existed only in 
their corona-collapsed/hydrophobic state whilst at 37 °C (standard incubator 
temperature) thus ensuring in vitro cell uptake could be efficiently monitored 
without concerns over an unintended change of state.  
To determine the Tt of each polymer, UV-vis spectrophotometry was utilised, 
with Tt approximated via determination of the cloud point of the NP 
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suspension. The cloud point is referred to as the point at which the NPs lose 
their colloidal stability and begin to phase separate. Although the cloud point 
is not a quantitative representation of the LCST, it is a close and reliable 
approximation. This is because the cloud point is the bulk representation of 
the precipitation caused by the phase separation of polymers when the 
temperature of the solution reaches the polymer LCST. 
The cloud points were measured by heating NP suspensions at a constant rate 
(0.5 °C/min) and reading the optical density measured at 550 nm. For P1-4 for 
both 65:35 and 75:25 PLGA core Tt ranged from 42 – 64 °C, Figure 18. The two 
different cores had a negligible effect on the Tt of each NP, the only exception 
seen in P4 which demonstrated an increase of 2.5 °C between the 65:35 and 
75:25 cores. 
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Figure 18 Tt data for P1-P4. A) 65:35 PLGA core P1-4. B) 75:25 PLGA core P1-P4. The 
inflection point in the optical density data denotes the Tt of each NP. The OD data was 
recorded at 550 nm from samples heated at 0.5 °C/min. Concentration of each NP sample 
was 10 mg/mL.  
As the cloud point is a measure of when the bulk suspension loses colloidal 
stability it is possible that the measurement would be susceptible to 
concentration changes. It is possible that when the concentration of NPs is 
lowered the rate at which the NPs will aggregate together upon chain collapse 
will be slower, due to their being less NPs in the vicinity of each to aggregate 
quickly. If this was indeed the case then it would take a longer time period to 
cause a measureable change in the OD. To understand how much this would 
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affect P1-P4, the cloud point of P1 was measured at 5 and 10 mg/mL in both 
water and phosphate buffered saline (PBS) as a more biologically relevant 
medium, Figure 19. There was no observable difference in the cloud point for 
P1 NPs when the concentration of the suspension was halved, however when 
the NPs were in PBS the cloud point was observed at 3 °C lower that the 
sample prepared in water. This shows that the PPGMA-OEGMA corona NPs 
do not have a concentration dependant cloud point. The reason for the 
reduction in Tt when the NPs are suspended in PBS is due to the salting 
effect.133 The salts in PBS, of which NaCl is the main constituent, interferes 
with the hydrogen bonding sites of the water by binding to the O atoms of the 
PPGMA and OEGMA. This causes there to be less energy needed to break 
these hydrogen bonds and thus facilitate phase separation. Recent molecular 
dynamics on poly(N-isopropylacrylamide) showed that when  NaCl, NaBr, NaI 
and KCl salt solutions were used the cations had a strong affinity for the 
amide O and this was what lowered the observed LCST in the presence of 
salts.134 
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Figure 19 Tt data for P1 in water at 5 and 10 mg/mL and PBS at 5 mg/mL 
The decrease in Tt observed when the NPs were suspended in salt containing 
solutions is something that needs to be considered when NPs are taken in 
vitro/in vivo and therefore needs thoroughly tested. 
Although it has been shown that the Tt could be altered by simply modifying 
the ratio of PPGMA to OEGMA475 the lowest observed Tt in each of these 
instances was 40 °C; when the NPs were assembled in PBS, 6 °C higher than 
the desired range for the Tt. These temperatures also contradicted those Tt’s 
previously reported (31 – 55 °C).127 The reasons behind the conflicting Tt 
results have yet to be determined as the synthesised polymers had very 
similar Mn and Đ values. 
Given the observed increase in Tt, the PPGMA monomer was substituted for 
DEGMA (similar to the OEGMA monomer but with only two ethylene glycol 
repeat units). Lutz et al have shown that when copolymers were synthesised 
using these monomers the Tt could be finely controlled and that the degree of 
polymerisation (DP) had no effect on the Tt.
60 In addition to substituting 
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PPGMA for DEGMA, it was chosen at this point to only use PLA as the 
macroinitiator both due to the ease of synthesis and reproducibility of 
synthesis, i.e. no lactide:glycolide inconsistencies.  
 
Scheme 5 PLA-b-((DEGMA)-stat-(OEGMA)) polymer synthetic scheme using AGET ATRP. 
The PLA-b-((DEGMA)-stat-(OEGMA)) thermoresponsive polymers were 
synthesised as previously reported for the PLGA-b-((PPGMA)-stat-(OEGMA)) 
thermoresponsive polymers, Scheme 5. Using this method, a variety of 
polymers were assembled with varying ratios of DEGMA to OEGMA, a 
selection of which are shown in Table 6. 
  
Table 6 Reaction and mass information for PLA-b-((DEGMA)-stat-(OEGMA)) polymers. 
Polymer 
PLA Mn 
(kDa) 
Total Mn, 
GPC (kDa) 
ÐGPC 
Mn 
(kDa)NMR
 
OEG9MA, 
theoretical 
(mol%) 
OEG9MA 
content 
(mol%)NMR 
NP Tt (°C) 
P6 14.7 37.3 1.32 34.8 0 0 28 
P7 14.7 50.2 1.29 38.7 5 6 35 
P8 14.7 52.1 1.26 37.4 10 8  42 
P9 14.7 41.7 1.38 39.7 20 17 50 
P10 13.1 36.6 1.45 28.7 35 30 64 
P11 13.1 47.5 1.46 30.5 50 44 78 
GPC: CHCl3 mobile phase flow rate: 1 mL/min. Oven temp: 30 °C Samples dissolved in CHCl3 prior to analysis. NMR: Bruker 400 Ultrashield at 400MHz and 25 °C. 
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As the data in Table 6 shows, the results are similar to those from the 
previous PLGA thermoresponsive polymers with all displaying a low Ð (< 1.5) 
and a consistent Mn across the series, Figure 20. 
 
Figure 20 GPC traces overlaid for P6-11. Solvent: chloroform.  
The important aspect of these polymers is that the resultant OEGMA content 
is agreeable with that of the feed ratio as this controls the transition 
temperature of the NPs. When the polymers were analysed by 1H NMR it was 
possible to calculate the percentage content of OEGMA (with the remainder 
made up of DEGMA) in each polymer. For each polymer P6-P11 the calculated 
OEGMA content mostly agreed with the theoretical content; there was a 
maximum 6 % difference between calculated and theoretical OEGMA for P11. 
To ascertain whether the change from PPGMA to DEGMA resulted in a drop in 
recorded Tt, NPs of P6-P11 were assembled and tested. 
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2.3.3  Thermoresponsive properties of P6 – P11 
The NP Tt for P6-11 was determined using the method previously described 
for P1-P5. 
 
Figure 21 Comparison of the Tt of NP vs OEGMA content in the NP corona. Each data point 
is the mean of N=3 experiments.  
The Tt of P6-P11 NPs was compared with the OEGMA content and was found 
to exhibit a positive linear relationship across the entire series of polymers, 
Figure 21. The Tt of each of these polymers was in the range that was 
expected, i.e. from 28 °C for P6 through to 78 °C for P11. The data agreed 
with that previously reported for p(DEGMA-b-OEGMA). For 5 % OEGMA the Tt 
would be 32 °C,60 and the observed Tt for P7 (6 % OEGMA) was 35 °C. As there 
was little difference in the Tt it can be concluded that the addition of PLA to 
p(DEGMA-b-OEGMA) had no effect on the resultant Tt of the NPs, as 
expected.  
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This result allows for a specific Tt to be selected and the associated ratio of 
OEGMA:DEGMA to be determined, without the need for multiple syntheses.  
For the aforementioned NPs to be used as a drug delivery vehicle in-vivo the 
transition of the NPs between their colloidally stable and unstable states 
would need to be reversible. This w`ould limit any potential off target effects 
by ensuring the NPs remained in the hydrophilic, chain extended state when 
the NPs are not being heat activated. 
 
Figure 22 Reversibility in polymer collapse as shown by 8 heat/cool cycles where a large 
increase in optical density was measured upon each heating cycle.  
To test the reversibility of the NP transition a sample of P7 NPs were heated 
to 45 °C (beyond Tt) and cooled to 20 °C (below Tt) at 1 °C/min intervals and 
the change in optical density (550 nm) measured during each cycle, Figure 22. 
For each heat/cool cycle the optical density increased upon heating and 
reduced upon cooling as would be expected for NPs switching from colloidally 
unstable (high temp.) to stable states (low temp.). 
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The Tt data acquired for the PLA-b-((DEGMA)-stat-(OEGMA)) polymers 
confirmed this system as ideal for further study due to a defined and 
reversible Tt. From the library of polymers, two polymers with 5 % and 12 % 
OEGMA, respectively were synthesised to contain an additional red 
fluorescent rhodamine B tag for testing in-vitro.  
2.3.4  Fluorescent thermoresponsive polymer synthesis for in-vitro studies 
 
Figure 23 rhodamine B methacrylate dye 
The addition of rhodamine B methacrylate dye ([dye]:[monomer], 1:1000) 
during the AGET ATRP process enabled the NPs formed to be fluorescent and 
thus visible for microscopy and flow cytometry experiments. The aim was for 
the Tt of each polymer when assembled into NPs to be in the region of 35 °C 
and 45 °C respectively, below and above body/incubator temperature, 37 °C, 
for in-vitro testing. 
Table 7 Reaction and mass information for PLA-b-((DEGMA)-stat-(OEGMA)) polymers to be 
used for in-vitro studies.  
Polymer 
PLA 
Mn 
(kDa) 
Total 
Mn, GPC 
(kDa) 
ÐGPC 
Mn 
(kDa)NMR
 
OEG9MA, 
theoretical 
(mol%) 
OEG9MA 
content 
(mol%)NMR 
NP Tt 
(°C) 
P12 14 42 1.44 35 5 5 27 
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P13 14 39 1.37 27 12 10 39 
 
The two polymers were synthesised successfully with an OEGMA content in 
line with that desired, 5 and 10 mol% respectively, with a Tt of 27 °C for the 
first of the synthesised polymers, P12, and 39 °C for the second, P13. 
Although the measured Tt was slightly lower than desired they were in the 
range considered acceptable for further in-vitro testing. 
Thus far only the thermoresponsive element of the drug delivery vehicle had 
been investigated, once the two rhodamine tagged polymers of desired Tt had 
been generated the remaining element of the ‘hide-and-reveal’ motif was 
synthesised. 
2.3.5  Step Three: Folate tagged polymer synthesis 
To add the hide-and-reveal motif of these NPs three amphiphilic polymers 
were synthesised with 3 different lengths of PEG linkers, each with a terminal 
folate group for targeting. 
PEG400, PEG3k and PEG10k were chosen to act as spacers between the PLA core 
and the folate tag. This polymer once assembled would then be mixed in with 
the thermoresponsive polymer and mixed NPs would be assembled with the 
hide-and-reveal motif. 
The three different length spacers would facilitate the folate being situated at 
a certain distance from the core of the PLA, so may or may not be shielded by 
the thermoresponsive corona depending on the length of linker. 
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If we assume that all the polymers are in their linear elongated structure, the 
lengths of each polymer can be calculated using cosine rule. I.e. using PEG as 
an example: 
 
Figure 24 determining the length of PEG using the cosine rule 
Each repeat unit of PEG consists of C-C-O triangle and C-O-C triangle, denoted 
in Figure 24 by a and b, respectively. To determine the length of one repeat 
unit: 
𝐜 =  𝐚 +  0.5𝐛 
Using cosine rule: 
𝑎2 =  0.1542 +  0.142 − 2(0.154 × 0.14)𝑐𝑜𝑠 109.5° 
𝑎 = 0.240 𝑛𝑚 
𝑏2 =  0.142 +  0.142 − 2(0.14 × 0.14) 𝑐𝑜𝑠104° 
𝑏 = 0.229 𝑛𝑚 
𝑐 = 0.355 𝑛𝑚 
Therefore with c being the length of one repeat unit, by multiplying this be 
the DP the lengths of each polymer can be determined, Table 8. It is also 
possible to calculate the freely-jointed random walk end to end distance if the 
polymers are assumed to be in their theta solvent:  
a 
b 
c 
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𝑟𝑓
2 =  𝑛𝑙2 
Where rf is the random walk end to end distance, n is the number of bonds in 
the chain and l is the length of bond.135 The random walk end to end distance 
is however unrealistic as it does not take into account any bond angles or the 
interaction between the chain elements and thus the rigidity of the polymer 
chains; however this can serve as a minimum size for the purposes of the 
comparison between polymer chains. By comparing the two results together 
it can be postulated that the actual length of the polymers will be part way 
between these minimum and maximum distances.  
Table 8 Length of polymers used for hide-and-reveal motif. Polymers were assumed to be in 
theta solvent and thus in their fully elongated structure 
Polymer 
Length of thermoresponsive 
corona (nm) 
Length of PEGx linker (nm) 
 
Fully 
elongated 
Random walk 
(end to end) 
Fully 
elongated 
Random walk 
(end to end) 
P12 37.7 3.8   
P13 20.0 2.7   
PEG400   3.2 1.1 
PEG3k   24.1 2.9 
PEG10k   80.2 5.3 
From the 3 PEG linkers, two, PEG400 and PEG3k should have their folate tag 
‘hidden’ when the thermoresponsive corona is in its fully hydrated state 
however, PEG10k has length larger than the thermoresponsive corona and so 
should be protruding from the surface of the NP corona and ‘visible’ at all 
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times. This would give the option of comparing the 3 types of folate tagged 
NPs and whether the length of linker has any significant effect on the uptake, 
this will be investigated in Chapter 4. 
All 3 polymers were synthesised in the same manner. The PEG linker was 
purchased with a terminal amine and either a terminal alkyne or azide. The 
free amine was used for the ROP of lactide to form PLA-PEGx-alkyne/azide, 
followed by copper catalysed cycloaddition to attach the folate molecule to 
the terminus of the chain, Scheme 6. 
 
Scheme 6 Synthetic scheme for synthesis of PLA-PEGx-folate 
Table 9 Mass information for PLA-PEGx-folate targeting polymers 
Polymer Mn,GPC kDa Đ GPC 
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PLA-b-PEG400-folate 19.5 1.19 
PLA-b-PEG3k-folate 17.2 1.34 
PLA-b-PEG10k-folate 22.5 1.45 
 
Each PLA-PEGx-folate was successfully synthesised with a consistent Mn  and 
low Đ and taken forward for further testing which will be discussed further in 
Chapter 4. 
2.4  Conclusions 
Many issues were encountered during the synthesis of a 50:50 PLGA suitable 
for further ATRP synthesis both in terms of achieving a desirable Mn and with 
a required solubility. Establishing a system in which the glycolide was the 
minor component (65:35, 75:25 and 100:0) PL(G)A was successfully 
synthesised to the required Mn for the thermoresponsive synthesis.  
Although a library of PLGA-b-((PPGMA)-stat-(OEG8-9MA)) was successfully 
synthesised the Tt of NPs assembled for each was too high for further testing 
(> 40 °C). PLA-b-((DEGMA)-stat-(OEGMA)) however showed Tt from 28-78 °C. 
Two types of the PLA-b-((DEGMA)-stat-(OEGMA)) were then chosen (5% and 
12% OEGMA) for taking forward to further testing. The formulation of these 
NPs is investigated in Chapter 2. Three PLA-PEGx-folate polymers were also 
synthesised, with different lengths of PEG, for mixing with thermoresponsive 
polymer to make NPs with the ‘hide-and-reveal’ motif. These were further 
tested in vitro and the results are discussed in Chapter 4. 
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3  Development of a reproducible method for nanoparticle 
assembly 
3.1  Introduction 
In Chapter 1 the synthesis of thirteen polymers (P1-P13) was reported. For 
these polymers to be considered as a suitable foundation for the targeted 
drug delivery device under investigation it must first be possible to formulate 
the polymers into nanoparticles (NPs). The NP formulation process must 
adhere to two criteria; firstly, it must be robust, allowing for the reproducible 
production of NPs within a precise size range, secondly, the NPs must be 
capable of encapsulating hydrophobic drug molecules  
A common method of assembling nanoparticles is nanoprecipitation, or 
interfacial deposition. This method involves the addition of a polymer rich, 
water miscible, organic solution to water or predominantly aqueous phase. As 
the organic phase disperses and the polymer comes into contact with the 
aqueous phase, the hydrophobic block of the polymer forms the inner core of 
the NP, with the hydrophilic block forming the outer shell/corona, Figure 25. 
 
Figure 25 General schematic of nanoprecipitation. Free polymer on right hand side in 
organic solvent formed into NPs by adding to aqueous solution, hydrophobic (blue) section 
of polymer forms core of NP with hydrophilic (orange) section forming the corona.  
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This technique is typically executed by adding the polymer rich solution to a 
stirred aqueous solution using a dropper, e.g. pipette or dropping funnel, 
136,137 and is one of the most commonly reported methods due to its ease of 
use without the requirement for any specialised equipment. 
More recently however, the use of microfluidics for NP assembly has become 
an increasingly common technique for a variety of NP formulations, such as 
inorganic core-shell NPs138-140 and polymeric NPs.141-143 This technique allows 
fine control over solvent flow with mixing at the milli- to microsecond range 
possible.140 This technique generally involves the assembly of microfluidic 
chambers or chips to house channels capable of holding nano- to microlitre 
volumes. A disadvantage of this technique is that it can only be used for 
preparing NPs for in vitro studies as the low volumes and flow rates protract 
the length of time taken to assemble the necessary quantity of NPs for in vivo 
experiments. It has been suggested that the use of parallel microfluidics 
would retain the structured and reproducible assembly of NPs but increase 
the quantity of NPs produced at a time.144 
The recent advancement in microfluidic technology for the controlled 
assembly of NPs is here applied using a very similar strategy for the assembly 
of PLGA and PLA core NPs.  
 
3.2   Methods 
Polymers used for this formulation study are described in Chapter 1 (P1 – 
P13). 
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Figure 26 A) Structure of PLGA-b-p(PPGMA-stat-OEGMA) (P1-P5). B) Structure of PLA-b-
p(DEGMA-stat-OEGMA) (P6-P13). 
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Table 10 Polymers used for the optimisation of NP assembly. For synthesis information 
consult Chapter 1. Polymers denoted with ‘a’ have 65:35 PLGA core, ‘b’ are 75:25 PLGA 
core. 
Polymer Type of core PPGMA:OEGMA mol% OEGMA 
NP size 
(DLS – nm) 
P1a/b PLGA 3:1 
 
34 ± 6 
P2a/b PLGA 2:1 
 
39 ± 3 
P3a/b PLGA 1:1 
 
29 ± 4 
P4a/b PLGA 3:2 
 
41 ± 7 
P5a/b PLGA 4:1 
 
30 ± 2 
P6 PLA 
 
0 60 ± 2 
P7 PLA 
 
6 75 ± 3 
P8 PLA 
 
8 102 ± 12 
P9 PLA 
 
17 86 ± 8 
P10 PLA 
 
30 78 ± 4 
P11 PLA 
 
44 92 ± 7 
P12 PLA 
 
5 78 ± 6 
P13 PLA 
 
10 93 ± 5 
 
3.2.1  Solvent drop method 
A known concentration of polymer in acetone (10 mg mL-1) was added drop-
wise using a Pasteur pipette to an equal volume water or PBS stirred at 500 
r.p.m. Residual acetone was allowed to evaporate by stirring the suspension 
at room temperature overnight. 
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3.2.2  Solvent flow method 
Two syringe pumps were used to enable precise flow control of aqueous and 
organic phase. One syringe contained the polymer dissolved in acetone (10 
mg mL-1) the other contained the aqueous phase (e.g. water or PBS). The 
syringes were connected with polyether ether ketone (PEEK) tubing (i.d. 
0.02”) to a T-connector where mixing occurred. The flow rates of each 
solution were kept constant throughout. Nanoparticle suspensions obtained 
were stirred at room temperature to allow the residual acetone to evaporate. 
3.2.3   Drug encapsulation 
Using the syringe pump method, 5 wt% of drug molecule (Doxorubicin) was 
dissolved in acetone with the polymer under investigation. Once residual 
acetone had evaporated (achieved when overall volume had reached that of 
the aqueous content), residual free drug was removed by gel filtration (PD-10 
column). 
To determine the extent of encapsulation, a sample of NPs (500 μL) was 
freeze-dried prior to dissolving in DCM. The absorbance was measured on 
Varian Cary UV-visible spectrophotometer and the resulting mass of drug was 
quantified from a standard curve. 
3.3   Results and discussion - Nanoparticle assembly: how to 
enhance size reproducibility 
3.3.1  Solvent drop NP formation 
The first method used to assemble the thermoresponsive nanoparticles was 
the solvent drop method, Figure 27, a common and widely used technique for 
nanoparticle assembly. A selected amount of polymer (10 mg/mL) was 
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dissolved in acetone and the solution added in a dropwise manner to water or 
PBS stirred at a constant rate (500 r.p.m). The ratio of aqueous to organic 
phase remained constant at 1:1 v/v. Upon complete addition of the polymer 
solution, the resultant mixture was left to stir at room temperature to allow 
the acetone to evaporate.  
 
Figure 27 Schematic of solvent drop method for NP assembly. Polymer in acetone solution 
is added to a stirred aqueous solution using a syringe or dropping funnel. The resulting 
suspension is stirred at constant rate until acetone has completely evaporated.  
Initially, P1 – P5 were used to probe the efficiency of this method and to 
evaluate its capability to reproducibly generate NPs within a certain size 
range. The dynamic light scattering (DLS) data for NPs P4a + P5a indicates the 
presence of two size populations of NPs for each polymer, one at 25-30 nm 
and the other at   1̴50 nm, Figure 28. This data is representative of data 
generated for other polymer NP’s of P1 – P3. The data shown is the result of 
numerous iterations of both stir speed and rate of solvent addition. 
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Figure 28 DLS data of 65:35 PLGA core P4 + P5 polymer nanoparticles,sizes are radii and all 
in nm. A) P4 intensity DLS. B) P5 intensity DLS. C) + D) Correlation curves for 3 batches of 
NPs the overlap of each curve shows the similarity between each batch.  
The morphology of the NPs generated using the method above was assessed 
by transmission electron microscopy (TEM). The results of TEM imaging for 
NPs of P1 – P4 (65:35 and 75:25) are shown in Figure 29.
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Figure 29 TEM images of thermoresponsive NPs. Samples prepared by diluting a sample of the NP suspension with a phosphotungstic acid (3 % w/v) stain. All scale bars 
are 500 nm.  
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In each image there is an observable variation in NP sizes where one size 
range formed the majority of the population distribution in each instance; this 
data agreed with the representative DLS data above. Furthermore, the TEM 
imaging confirms the morphology of the resulting NPs to be spherical. To 
compare the sizes of the NPs with those measured by DLS image analysis 
software was used on the TEM images. As an example, the NPs of P4 were 
found to range from 17 – 50 nm in diameter, Figure 30. These sizes are within 
the limits determined by DLS measurements for the smaller population (25 – 
30 nm). There was a noted absence of the larger population within the TEM 
images. There are two possible reasons for this; firstly, the drying process 
associated with TEM sample preparation resulted in the loss of water from 
the corona of the NPs, thus polymer shrinking occurred and smaller particle 
sizes were observed. Secondly, the imaged sample may not have been typical 
of the system as a whole, only containing a few NPs of larger size and so the 
population distribution was not accurately represented.  
An alternative explanation for the limited number of larger NPs seen in TEM 
imaging may relate back to the initial DLS analysis. Intensity measurements by 
DLS are proportional to d6 (where d is the diameter of the NP), therefore 
although the DLS analysis is suggestive of a population of NPs with a larger 
diameter, there are likely few of these NPs present in the sample. The NP 
sizes observed are broadly in agreement with those observed for similar 
polymer types, PLA-b-PEG.145  
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Figure 30 TEM image of P4 NP with a selection of sizes measured using TEM imaging 
software. Scale bar 500 nm  
Additional testing was carried out in cell culture media for a prolonged period 
of exposure to test whether proteins would be adsorbed to the surface and 
affect the NP size.  
 
3.3.2  Stability and thermoresponsive properties of NPs in cell culture 
media 
As the NPs assembled using PLA-b-((DEGMA)-stat-(OEGMA)) were intended 
for testing within cell systems, it was important to determine whether the cell 
culture medium would alter the transition temperature (Tt) or stability of the 
NPs. The NPs were suspended in RPMI media containing 10 % foetal calf 
serum and PBS as a comparison. The NPs were tested at 4 mg/mL and 0.4 
mg/mL to ensure dilution also had no effect on the Tt. P12 and P13 were 
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chosen for this study as these were rhodamine tagged for the intended cell 
studies. 
 
Figure 31 Tt data for P12 NPs (top) and P13 NPs (bottom). For both types of NPs Tt was 
determined using UV-vis spectrophotometry reading the abs at 550 nm every 30 seconds. 
Cuvettes were heated at 0.3 °C/min.   
The addition of cell media and protein from the foetal calf serum was found 
to have no effect on the overall Tt of the NPs of both P12 and P13, Figure 31. 
This result is suggestive that the proteins are not interacting with the 
thermoresponsive corona of the NPs. Upon dilution of the NPs, the Tt also 
remained the same in both environments with only a slower overall ‘clouding’ 
of the suspension noted; this was shown by the gradient of the curve for 0.4 
mg/mL being less than that of the 4 mg/mL NPs. The cause of the more 
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gradual gradient and lower optical density is due only to the lower 
concentration of NPs present. With a less concentrated suspension of NPs the 
change in recorded optical density (due to light scattering) will be less than 
the higher concentration suspension. As the polymer chains collapse upon 
reaching their lower critical solution temperature the hydrogen bonds are 
broken between the water and the polymer. This in turn makes the NPs 
become hydrophobic and will become attractive to other hydrophobic NPs 
which bring about the overall colloidal instability of the bulk suspension. The 
less NPs present results in a longer time period for the bulk suspension to 
aggregate and the less aggregates present means less scattering, thus less 
change in optical density.   
In addition to ensuring the presence of proteins had no effect on Tt, the NPs 
were suspended in cell culture media with serum proteins for 6 hours to 
ensure there was no change to the dimensions of the particles, thus stability 
of particles. The samples were analysed using DLS measurements, Figure 32. 
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Figure 32 NP stability in RPMI containing 10% FCS at 37 °C for 6 h. NPs were incubated in a 
water bath containing a shaker moving the samples at 100 r.p.m. A 100 μL sample was 
removed and diluted with 900 μL distilled water for analysis by DLS. Data shown is from 
N=7 replicate readings.  
The DLS intensity measurements showed only a slight increase in size of NPs 
at the 6 h time point of the study in the presence of serum proteins, the size 
of the NPs remained between 100-150 nm. There was also no observable 
precipitation of NPs during the 6 h incubation period. This is important as it 
indicates there is likely no substantial protein adsorption to the surface of the 
NPs which would inhibit their use for cell targeting and possible long term 
circulation within the body. Although it has been shown previously that PLA-
PEG NPs do show some sign of adsorbing plasma proteins (especially 
adsorbed albumin, fibrinogen (α, β and γ), IgG γ, Ig light chains, apos A-IV, E, 
A-I and C-III) to the surface when mixed with human blood plasma depending 
on length of PEG chains.146 It was also found that when comparing with PLGA 
and polycaprolactone core NPs the proteins adsorbed depended on the 
hydrophobicity of the core. This would need to be tested in the future to 
ensure the long circulation capacity of these NPs with PEGMA corona.  
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NP size is an important consideration from a pharmacokinetics view point. To 
be effective as a drug delivery device the NPs need to get to the area of action 
in a sufficient quantity to be effective. To reach the diseased area numerous 
barriers that exist in the human body to protect from foreign bodies need to 
be overcome. As the method of delivery of these NPs would be intravenous 
injection some of these initial barriers, such as breakdown in the gut and 
crossing gastrointestinal tract, would be avoided. The largest barrier to 
prolonged circulation of the NPs is the reticuloendothelial system (RES) and 
hepatic clearance. Shielding NPs from proteins within the body ensures the 
minimisation of opsonisation and thus phagocytic recognition and clearance 
by the RES;147-149 the attachment of PEG to the surface was found to 
substantially reduce the quantity of apolipoproteins present on the surface 
compared to pure PLA NPs (~80 % reduction).146 It has been shown that NPs 
can be cleared within seconds of intravenous delivery of the formulation due 
to the high concentration of phagocytic cells in the liver and spleen;5,150 
therefore with the PEGMA corona acting as a shield similar to the shielding 
effects of PEG, the NPs would be expected to have an extended circulating 
time to ensure higher uptake via EPR effect. NPs with a hydrodynamic 
diameter larger than 200 nm, whether shielded or not, are rapidly cleared by 
the bloodstream.151 This means that even a PEGylated 200 nm diameter NP 
would be cleared much faster by the renal system than a 60-100 nm NP. In 
addition the size of NPs also affects the biodistribution as NPs < 150 nm 
produced an increased uptake in the bone marrow of rabbits; NPs that were 
250 nm were mostly sequestered in the liver and spleen.152 If the NP 
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formulation is to be effective the particle size and distribution need to be 
consistent from batch to batch.. Additionally, the NP size controls the rate at 
which the drug would be released in vivo, either retarding release or 
facilitating a burst release profile. 
The NPs assembled using the solvent drop method were between 60 - 150 nm 
and the TEM also showed a wide dispersity within each NP sample. 
Controlling this size is important to ensure the NPs behave in the same 
manner once delivered to the patient, i.e. clearance level and targeting to 
tumour site.  
 An alternative controlled solvent flow method was investigated in an attempt 
to reduce the size variability observed for the solvent drop method.  
3.3.3  Solvent flow NP assembly 
NP formulation using a solvent flow set-up affords a more controlled method, 
utilising syringe pumps and a small mixing device, to deliver the aqueous and 
organic phase in desired ratios and at a constant rate. Advantages of this 
technique include the opportunity to remove the potential for human error 
during the addition of the polymer solution; additionally it ensures the mixing 
occurs in a controlled manner via the T-junction, Figure 33, facilitating the 
reproducible formulation of NPs ensuring they assemble with a consistent size 
distribution.  
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Figure 33 Schematic representation of syringe pump method for NP assembly. Mixing 
chamber is the T-junction.  
P6 was used as a representative of the PLA-b-p(DEGMA-stat-OEGMA) library 
to assess the syringe pump method for enhanced reproducibility over the 
previously described solvent drop method. The concentration of the polymer 
was kept constant between methods (10 mg/mL), with a final aqueous 
volume of 5 mL. The flow rates for both organic and water phases was 1 
mL/min. 
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Figure 34 DLS data for comparison between solvent drop and solvent flow method. A) DLS 
intensity measurement of 3 replicate NPs formed from solvent drop method (10 mg/mL 
polymer concentration, 2.5 mL acetone, 5 mL PBS, stir speed 500 r.p.m). B) DLS intensity 
measurement of 3 replicate NPs formed from syringe pump method (1 mL/min flow rate, 
10 mg/mL polymer concentration, 2.5 mL acetone, 5 mL PBS (2.5 mL for flow then diluted 
with further 2.5 mL). A, B and C are 3 replicate intensity measurements.  
DLS data validated the syringe pump method as a superior method for 
producing NPs with a consistent size distribution (Figure 34B) when compared 
to the solvent drop method. The solvent drop method showed an observable 
size difference between all 3 replicates. The difference most likely occurred as 
the addition of solvent to water to instigate the NP assembly is not a 
controlled process. Slight variations in the rate of addition and size of droplet 
can cause differences in how the polymers will begin to interact with the 
water and thus NPs assembled were not consistent in size. During the solvent 
flow method, each stream, solvent and aqueous, were mixed together in a 
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consistent manner within a small area in the T-junction. The flow of solvent 
ensured that the polymer in the organic phase is mixed rapidly with the 
aqueous phase, resulting in the consistent nature of the NP assembly across 
batches, as observed in the overlap of each DLS intensity measurement of NP 
assembly repeats. 
To further investigate the solvent flow method of NP assembly, different flow 
rates were chosen to determine whether this would impact upon the size of 
NPs assembled. Flow rates were chosen from 0.1 mL/min to 1 mL/min and 
each NP sample was analysed by DLS,  . 
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Figure 35 DLS data for NPs assembled under various flow conditions. Flow rate of both syringes remained equal. (Intensity: intensity average distribution, Mass: mass 
average distribution and number: number average distribution of NPs as measured by DLS.) Data representative of 3 replicate samples.   
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It was found that when the flow rate was ≥ 0.2 mL/min the size of the NPs 
produced remained consistent. It was only when the flow rate was reduced to 
0.1 mL/min that the NPs formed were of a larger average size and the range 
of NP sizes were more diverse. The least disperse sample was that observed 
for particles assembled between 0.2 - 1 mL/min. There was slight broadening 
of the DLS intensity peak representative of 100 nm however the NP 
populations observed was representative of the lower flow rates tested.  
Further to investigating the effect the flow rate had on the NP size 
reproducibility, the ratio of solvent to buffer was also explored. P6 was used 
as above to further the proof of concept of this method. For this study the NP 
concentration, 10 mg/mL was kept constant. The rate of addition of the 
buffer was changed so the overall solvent to buffer ratios was as follows: 1:1, 
1:2, 1:3, 1:4 and 1:5. Once the acetone had evaporated a sample of equal 
concentration was removed from each test for analysis by DLS. When the flow 
rates of each stream remain equal the NPs formed are of a reproducible size 
as shown previously in Figure 33. When the flow rate of the buffer stream is 
increased, thus increasing the buffer:acetone, the batch-to-batch 
reproducibility of the NP size decreases; this is shown in Figure 36 by the DLS 
intensity no longer overlapping when the ratio is 1:2-1:5. As the ratio is 
pushed to the extremes of 1:4 and 1:5 a dual size population begins to 
emerge. It was concluded from this optimisation of the solvent flow method 
of NP assembly that if the flow rate is equal for both streams and the flow 
 
111 Development of a reproducible method for nanoparticle assembly 
rate was > 0.2 mL/min NPs of a reproducible size and distribution were 
assembled.  
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Figure 36 DLS intensity measurements of NPs formed from P6 by varying acetone:PBS buffer as proof of concept. When the flow rates of both acetone and PBS buffer 
were equal reproducible sized NPs were observed.  When the ratio of buffer was increased the size of NPs were no longer reproducible. 2 distinct populations were 
noted for 1:4 and 1:5 ratios.  
 
 
Overall these data for the solvent flow method of NP assembly were in 
agreement with those shown by Karnik et al. where homogeneous NP 
suspensions of PLGA-b-PEG  were achieved using a similar method within a 
pre-formed chip.143 When microfluidics are used the major advantage over 
the ‘bulk’ drop method is the consistency in size of NPs produced. However 
there remains a notable disadvantage and that is the rate of NP production. A 
method of avoiding this problem that other groups have utilised is to use 
parallel assembly using multiple chips. Although when this method was 
implemented the maximum rate of NP production was 84 mg/h, compared to 
2.5 mg/h for a single chip.144 This does mean that it still takes 18 minutes to 
assemble only 25 mg of NPs, which for a scalable and industrial process would 
be limiting as an inexpensive and high through-put method.153 With a polymer 
concentration of 10 mg/mL and flow rate of 1 mL/min the solvent flow 
method described above is capable of producing 600 mg/h. By using simple 
and cost-effective apparatus and without the need for prior assembly of a 
micromixer chip, this method can be considered universally accessible. 
Each type of NP assembled above using both techniques had a mean 
hydrodynamic diameter of < 200 nm. This is important for the passive 
targeting of NPs via the enhanced permeation and retention (EPR) effect. It 
has been summarised that NPs should be sub-300 nm to be possible to 
permeate through the leaky vasculature around tumour sites.6,154 As these 
NPs should be capable of passive targeting via the EPR effect, due to their size 
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and shape, the ability of the NPs to carry a drug payload for delivery was 
investigated. 
3.3.4  Capacity of nanoparticles for drug encapsulation 
The polymers described in Chapter 1 were shown to be capable of 
consistently assembling into NPs with a size of < 200 nm. The assembly 
method was tested to ensure it produced NPs which could efficiently act as 
drug carriers. This was to ensure that prior to any further in-vitro testing there 
was confirmation of drug encapsulation and therefore validation that the 
carrier was capable as acting as a drug delivery vehicle.  
Doxorubicin (dox) was chosen as a model hydrophobic drug due its 
hydrophobicity in its free base form (16 µg/mL at 25 °C)155 and thus 
problematic for oral and intravenous formulation at higher concentrations. 
Dox is used regularly as a test of encapsulation as it is an active drug 
molecule,38,156,157 used in the treatment of cancers,158 and allows for easier 
quantification of drug loading due to the presence of a chromophore. 
As previously discussed during the formation of NPs, section 3.3.3 , the 
solvent flow method was validated as the superior method for NP. With the 
knowledge that the flow rate could be altered without a detrimental effect on 
the NPs, the rate was investigated for any effect on drug encapsulation. 
Three flow rates were chosen, 0.5, 1.0 and 2.0 mL/min, with the 
concentration of polymer and doxorubicin remaining constant throughout. To 
ensure the dox was encapsulated as a free base 2 equivalents of triethylamine 
were added to the dox.HCl prior to mixing with P12. 
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Figure 37 Doxorubicin encapsulation within NPs assembled using the solvent flow method. 
There were minimal differences noted between the three flow rates chosen with no 
significant difference using Sidak’s multiple comparison test. Data shown is from 3 
independent repeats.  
The mass of drug encapsulated across the range of flow rates was 0.15-0.21 
mg/10 mg of NPs, Figure 37. For each of the repeats the quantity of drug 
encapsulated was found to be very consistent and the higher the flow rate of 
the syringe pump the more consistent the encapsulation achieved. The flow 
rate of mixing was determined not to have a significant effect on the amount 
of drug encapsulated, though the efficiency of the encapsulation appeared to 
drop when the flow rate was increased, however the efficiency did not drop 
below 29 %.  
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Table 11 Mass of drug encapsulated and encapsulation efficiencies by varying flow rate for 
NP assembly. 
Flow rate (mL/min) Mass of drug 
encapsulated (mg/10 
mg NPs) 
Encapsulation 
efficiency (%) 
0.5 0.214 ± 0.036 42.9 ± 7.2 
1 0.166 ± 0.010 33.2 ± 1.9 
2 0.146 ± 0.005 29.2 ± 1.0 
 
The amount of dox encapsulated within each particle was quantified and 
correlated with that reported by other groups (e.g. 0.32 mg/10 mg NPs for 
PEG-b-p(4-vinylbenzylphoshonate,159 0.18-0.22 mg/10 mg NPs for PEG-b-
(PLA-co-p(β-amino esters) 160 and 0.3-0.5 mg/10mg for PNIPAM-b-PLA NPs161)  
and  although it has to be noted that whilst the polymers used were different 
to those previously reported, they all were of the micellar NP type. This data 
confirmed the PLA-b-((DEGMA)-stat-(OEGMA)) NPs were capable drug 
carriers in line with the drug carrying capacities of similar types of core-shell 
NPs. It is worth noting at this point that these are still low amounts of drug 
being encapsulated. The standard dose of doxorubicin is 40 – 60 mg/m2 every 
21 – 28 days, for an equal dose 187 – 280 mg of these NPs would be required. 
This high dose of NPs could themselves then cause toxicity problems and the 
need for high amounts of polymer to be removed from the body. The 
advantage of using these types of NPs would be the targeting capabilities and 
accumulation via the EPR effect and addition of targeting ligand. The targeting 
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would cause NPs to accumulate and the tumour site and therefore dose their 
drug payload site specifically unlike the systemic release of free drug in 
standard chemotherapies. Due to this, a much lower dose would be required 
to provide effective treatment and thus lower quantities of NPs. 
The data to this point has shown that with the flow method of NP assembly 
the PLA-b-((DEGMA)-stat-(OEGMA)) polymers are capable of forming NPs 
reproducibly and within the size range desired for targeting via the EPR effect, 
sub-300 nm, in addition to being able to encapsulate a model hydrophobic 
drug. 
3.4   Conclusions 
Nanoparticles assembled using the solvent flow method offered enhanced 
reproducibility in size than those assembled by the solvent drop method 
across all the polymers tested. It was determined that the flow rate had a 
negligible effect on the size of NPs produced, this was most likely due to the 
stabilisation effect of the PEGMA chains forming the shell of the NPs. The NPs 
were capable of encapsulating a hydrophobic drug, doxorubicin, within levels 
observed by others with a maximum encapsulation efficiency noted of 43 % at 
a flow rate of 0.5 mL/min. The NPs produced were proven to be capable of 
being further tested in-vitro without detriment to the NPs and this is shown in 
Chapter 4. 
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4  Tuning the aggregation temperature of thermoresponsive 
nanoparticles 
4.1   Introduction 
Thermoresponsive nanoparticles are of interest for a range of applications, 
including sensing, diagnostics, adaptive optics and therapeutics.34,48,49,162,163 
The most widely studied nanoparticles of this type have been those intended 
for drug delivery, as the thermal triggering of a response in a carrier vehicle 
potentially allows exogenous control of particle location or drug release at a 
specific site.164-168 The thermoresponsive behaviour of these nanoparticles is 
usually bestowed by a surface corona of polymer chains which undergo a 
phase transition at a specified temperature in solution/suspension. The 
polymers themselves can be attached to a pre-formed nanoparticle, or can be 
self-assembling block co-polymers in which the inner block is solvophobic. In 
both cases the outer block or corona polymers exhibit changes in their 
solvation properties according to a change in temperature.  
The thermoresponsive polymers forming the corona are characterised by 
their Lower or Upper Critical Solution Temperature (LCST169 or UCST170) 
behaviour. For the LCST polymers, which have been most widely investigated 
for thermoresponsive nanoparticles, there is a critical temperature above 
which the polymer is only partially miscible in its solvent. Below the LCST, the 
polymer and the solvent are in the same phase, stabilized for example by 
hydrogen bonds between the solvent and polymeric chain. Above the LCST, 
the entropy-driven phase separation, results in collapse of the polymer 
chain.5 In the case of nanoparticles with a corona of polymers displaying an 
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LCST in water, the result of the polymer phase change is a decrease in surface 
solvation and an enhancement in apparent particle hydrophobicity. In pure 
aqueous suspensions, the LCST change of surface-displayed polymers results 
in a loss in colloidal stability, which then leads to particle precipitation or 
aggregation, dependent on concentration.162 In more complex environments, 
for example in biological fluids or in tissue, the phase changes and increase in 
surface hydrophobicity can result in differential protein adsorption or cell 
membrane interaction.171 These variations in bio-interfacial behaviour172 have 
been the most widely explored, as nanoparticles with these properties have 
been shown to exhibit controllable cell attachment and endocytosis.168,173   
As a result, there have been many efforts to tune nanoparticle-surface 
interactions by varying the temperatures at which phase changes occur. 
However, while there have been many papers showing that the LCST (and 
UCST) of linear polymers in solution can be controlled very precisely by co-
monomer content, molar mass and end-group content,61,174-177 the control of 
nanoparticle thermoresponsive properties has been more elusive.162,178  In 
part, this is because many studies have had a strong application focus, 
particularly in drug delivery, where interpretations of data are often 
confounded by alterations in polymer LCST by electrolytes133 and 
biopolymers, which in turn lead to highly variable protein adsorption or cell 
membrane association dependent on the specific environment.179 There are 
also the well-known issues in characterising polymers grown from the surface 
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of nanoparticles, or estimating polymer surface coverage when the polymers 
are grafted to pre-formed nanoparticles. 
The focus in this chapter was the exploration of routes by which precise and 
reliable thermoresponsive behaviour might be introduced into polymer 
nanoparticles, ultimately to develop predictable and constant release systems 
for drug delivery. It was also an intention to develop simple formulation rules, 
through which temperature response could be ‘dialled in’ to nanoparticles in 
a manner analogous to that in linear responsive co-polymers. The 
experiments in this chapter were thus designed to show how mixtures of 
different thermoresponsive polymers, based on oligo(ethyleneglycol) 
methacrylate monomers, and their resulting nanoparticles could be mixed to 
yield a range of temperature responses. This work was based on the 
hypothesis that aggregation temperature of nanoparticles can be controlled 
through 2 ways: a) mixing of pre-formed co-polymers of poly(lactic acid) 
(PLA)-block-poly(oligo(ethyleneglycol)methacrylate (p(OEGMA))–co-
poly(diethyleneglycomethacrylate) (pDEGMA) with varying LCST prior to 
nanoparticle formation through nanoprecipitation, and b) mixing of pre-
formed nanoparticles from constituent PLA-b-p-OEGMA-stat-DEGMAs of 
varying critical aggregation temperature, Figure 38. Copolymer and 
nanoparticle mixtures were evaluated at different constituent ratios, and the 
results of dynamic light scattering and turbidimetry experiments are shown to 
characterise size and transition temperatures of the resulting nanoparticles. 
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Figure 38 Structure of polymers and cartoon representation of different PLA-p(OEGMA) 
copolymers used to form thermoresponsive nanoparticles. Polymers with different ratios of 
OEGMA and DEGMA were mixed prior to nanoparticle formation or pre-formed 
nanoparticles with different aggregation temperatures were mixed. The resulting 
nanoparticles displayed variable aggregation temperatures dependent on the relative 
concentrations of the copolymers in the blends.  
4.2  Methods 
4.2.1   Synthesis of polymers 
The synthesis of polymers was carried out as discussed within chapter 1. 
Studies were carried out using P6-P11 as they were shown to produce 
nanoparticles (NPs) of a reproducible size and each had a different transition 
temperature (Tt) when assembled into NPs. - 
4.2.2  Characterisation of polymers - NMR 
1H NMR spectra were recorded at 20 °C on a Bruker instrument operating at 
400 MHz. Chemical shifts (δ) are referenced to CDCl3 (δ 7.26 ppm). The data 
were processed using MestReNova (v. 6.0.2) software. To determine degree 
of polymerisation (DP) of PLA macroinitiator the CH proton peak for lactide (δ 
5.3-5.1 ppm) was integrated in relation to protons on the terminal methyl of 
bromoisobutyryl bromide group (δ 1.96 ppm, 6H). The DP of copolymers were 
measured from DP of PLA (δ 5.3-5.1 ppm, set to 1H) then integrating the 
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protons on the terminal PEGMA methyl (δ 3.46-3.36 ppm, yH), y * (PLA DP) = 
copolymer DP. 
4.2.3  Gel permeation chromatography (GPC)  
GPC was performed on a Polymer Laboratories GPC 50 system equipped with 
a refractive index detector. Separations were achieved with a pair of PLgel 
Mixed-D (5 μm bead, 7.8 × 300 mm) columns with a matching guard (7.8 × 50 
mm) and chloroform as eluent at a flow rate of 1 mL min-1. Calibration was 
performed using narrow polystyrene standards (Polymer Labs) in the 
molecular weight range 0.13-210 kDa. Molecular weights and dispersity 
values were calculated using Cirrus GPC 3.0 software.  
4.2.4  Nanoparticles preparation 
The copolymers were dissolved in acetone at a concentration of 5 mg/mL and 
the solutions then mixed together at different ratios. Each blend was 
prepared using a double syringe pump. One syringe was used to introduce the 
polymeric solution; the other one to introduce an equal volume of water. The 
two solutions were loaded at the same time and mixed together in a T-
junction, using the same flow rate of 1 mL/min and loading the same volume 
for both syringes. Copolymers precipitated as a nanoparticle suspension at 
the interface between water and acetone. The final suspension was then left 
to stir at room temperature to allow the acetone to evaporate. 
4.2.5  Transition temperature determination by cloud point analysis 
The transition temperature (Tt) of the nanoparticles was determined by 
measuring the change in optical density of light using UV-vis 
spectrophotometry at 550 nm. This allowed for the increase in scattered light 
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upon sample aggregation to be measured (cloud point). Cloud point 
evaluations were performed using a Beckman Coulter DU-800 UV/Vis 
Spectrophotometer f working at concentrations ranging from 1 mg/mL. 
Samples were heated at a rate of 0.5 ˚C/min. Measurements were taken at 
0.5˚C intervals. The absorbance/optical density was converted to % 
transmittance (% transmittance = 10^(2-absorbance). Transmittance data 
were plotted versus temperature and Tt taken to be the point at which there 
was a 50% drop in the normalised transmittance (normalised to 100%).  
4.2.6  DLS measurements 
Dynamic light scattering was performed using a Viscotek Model 802 
instrument. Samples were taken from nanoparticle suspensions in ultrapure 
water (1:20 dilution), typically at 0.25 mg/mL and 25 °C measurements. 
Analyses were repeated 3 times for each sample, and a minimum of 7 
measurements was performed for each analysis. 
4.3   Results and discussion 
4.3.1  Thermoresponsive copolymer synthesis 
The prerequisite for the study was the preparation of co-polymers with a 
hydrophobic block to provide a driving force for self-assembly in aqueous 
media and a thermoresponsive segment to provide temperature-switchable 
behaviour. The characterisation data for P6-P11 are outlined in Chapter 1 and 
summarised in Table 12. When these polymers were assembled into single 
component NPs the Tt observed was between 28 – 78 °C. 
  
Table 12 Reaction and mass information for PLA-b-((DEGMA)-stat-(OEGMA)) polymers 
Polymer 
PLA Mn 
(kDa) 
Total Mn, 
GPC (kDa) 
ÐGPC 
Mn 
(kDa)NMR
 
OEG9MA, 
theoretical 
(mol%) 
OEG9MA 
content 
(mol%)NMR 
NP Tt (°C) 
P6 14.7 37.3 1.32 34.8 0 0 28 
P7 14.7 50.2 1.29 38.7 5 6 35 
P8 14.7 52.1 1.26 37.4 10 8  42 
P9 14.7 41.7 1.38 39.7 20 17 50 
P10 13.1 36.6 1.45 28.7 35 30 64 
P11 13.1 47.5 1.46 30.5 50 44 78 
GPC: CHCl3 mobile phase flow rate: 1 mL/min. Oven temp: 30 °C Samples dissolved in CHCl3 prior to analysis. NMR: Bruker 400 Ultrashield at 400MHz and 25 °C. 
 
 
 
 
Scheme 7 Synthetisof PLA-b-P((DEGMA)-stat-(OEGMA)) polymers used in this study 
The synthesised polymers were then formulated into kinetically-trapped core-
shell nanoparticles by two different methods. In the first method, solutions of 
individual block co-polymers in a good solvent for both blocks were added 
into water, thus producing single component nanoparticles. In the second 
method, solutions of two block co-polymers with different DEGMA:OEGMA 
ratios were added to water, producing blended polymer nanoparticles. 
Subsequently, the thermal transition temperatures (Tt) were measured for 
the single component NPs, the blended polymer NPs, and mixtures thereof. 
4.3.2  Single component polymer nanoparticles (NPs) 
The measured solution cloud points (Tt) of the block co-polymers in this study 
ranged from 28-78 °C with a linear increase in Tt with OEGMA content (Figure 
39).  
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Figure 39 Positive linear relationship of OEGMA content of single component NPs against Tt. 
The error bars represent standard deviation of 3 replicate tests.  
These values were in accord with those reported previously for similar block 
co-polymers of poly(poly(propyleneglycolmethacrylate)-co-OEGMA-b-
PLGA.49,180 and also for statistical poly(DEGMA-co-OEGMA) thermoresponsive 
polymers.60,133,181 It has been previously shown that the transition 
temperatures of POEGMA-based polymers are not dependent on the solution 
molar mass,60 and thus it is unlikely that the changes in particle transition 
temperature observed were a function of variations in molar mass in the 
constituent polymers. 
Copolymer blends were then investigated to determine what effect this had 
on the overall aggregation of the NP suspensions assembled.. 
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4.3.3  Nanoparticles formed by simultaneous co-precipitation of polymers 
with different individual cloud points 
In order to investigate possible control of cloud point by nanoparticle 
composition, mixtures of two PLA-b-P(DEGMA-stat-OEGMA) polymers each 
with different Tt were nano-precipitated from acetone into water to obtain 
the blended NPs. The ratios of the individual polymers in the formulated 
nanoparticles were systematically varied from 0, 25, 50, 75 and 100 weight 
percent such that any relative enrichment of one co-polymer over another in 
the surface corona might be detected.  
Table 13 NP formulations for blends of P6+P7 and P6+P9. 
NP formulation P6 (wt%) P7 (wt%) P9 (wt%) Tt (°C) 
NP6-71 100 0  28 
NP6-72 75 25  30 
NP6-73 50 50  33 
NP6-74 25 75  35 
NP6-75 0 100  38 
NP6-91 100  0 28 
NP6-92 75  25 40 
NP6-93 50  50 48 
NP6-94 25  75 50 
NP6-95 0  100 52 
 
The initial formulation series was based on one ‘standard’ polymer, P6, and 
then varying amounts of co-polymer with a higher OEGMA content (P7 and P9 
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and thus higher individual Tt), in the blend, Table 13. The compositions and 
the overall Tt values of the resulting copolymers are reported in Figure 40. 
When P6 was mixed with increasing quantities of P7 the Tt of the resulting 
NPs increased as the quantity of P7 increased. By comparison with the 
normalised transmittance curves, as well as the first differential of these 
curves, a distinct transition could be seen for each of the NP mixes analysed. 
In contrast when these data were compared with the blends of P6 with P9 (0 
mol% and 17 mol% OEGMA respectively) the change in Tt noted was not as 
well defined as that for the previous mixtures.NP6-93-5 all showed Tt at 
around 50 °C with only small differences between each. For this mixture the 
polymer with the higher Tt (P9) seemed to dominate the appearance of the 
cloud point and thus the measured Tt. It must also be noted that the overall 
turbidity measured for NP6-93-5 was higher than that for the NP formed solely 
from P6. When the Tt was plotted versus the OEGMA content for the blended 
polymer NPs of P6+P7 the relationship was very close to linear, as observed 
for non-blended polymer NPs, Figure 41. 
 
  
 
Figure 40 Optical density and transmittance data for the NPs formed from mixtures of P6 and P7/9. A) optical density data for P6 mixed with P7. B) Normalisation of the 
Abs data from A. C) Normalised transmittance data of data from A plus the 1
st
 differential of these curves to show the inflection temperature (cloud point). D)-F) as for 
A)-C) but with the P6+P9 mixtures. NP suspensions (1 mg/mL) were heated at a rate of 0.5 °C/min and measured every 0.5 °C.  
 
 
 
 
Figure 41 Positive linear relationship of the Tt from blend NPs of P6+P7 against OEGMA 
content. 
From these data it was initially hypothesised that for there to be cooperativity 
between the two polymers being mixed the OEGMA content between them 
should be similar. The cooperativity mentioned here relates to the binary mix 
of polymers within the blend having an influence on one another due to the 
presence of only one cloud point within the polymer blend NPs and not the 
presence of two transitions of the individual polymers within the blend.182 In 
experiments to test these individual hypotheses, first blends of NPs in which 
the constituent individual co-polymers displayed similar Tt values as well as 
both containing DEGMA and OEGMA were mixed. To determine if this was 
the case mixtures of P7 with P8 and P8 with P9 were assembled into NPs in 
the same manner as before and their Tt was measured for each, Table 14. For 
both these mixes there was some form of cooperativity noted in that the Tt of 
each blend was altered depending on the ratio of the constituent polymers. 
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Table 14 NP formulations for blends of P7+P8 and P8+P9. 
NP formulation P7 (wt%) P8 (wt%) P9 (wt%) Tt (°C) 
NP7-81 100 0  37 
NP7-82 75 25  39 
NP7-83 50 50  40 
NP7-84 25 75  41 
NP7-85 0 100  42 
NP8-91  100 0 43 
NP8-92  75 25 48 
NP8-93  50 50 50 
NP8-94  25 75 51 
NP8-95  0 100 49 
 
 
  
 
Figure 42 Optical density and transmittance data for the NPs formed from mixtures of P7+P8 and P8+P9. A) optical density data for P7 mixed with P8. B) Normalisation 
of the Abs data from A. C) Normalised transmittance data of data from A plus the 1
st
 differential of these curves to show the inflection temperature (cloud point). D)-F) 
as for A)-C) but with the P8+P9 mixtures. NP suspensions (1 mg/mL) were heated at a rate of 0.5 °C/min and measured every 0.5 °C.  
 
 
 
As apparent from Figure 42, while there were clear increases in Tt for the 
blended nanoparticles with increase in OEGMA content, the relationships 
were not linear. Further investigation was carried out using the higher Tt 
polymers (P9-P11) to ascertain whether linearity in Tt could be achieved for 
these polymers, Table 15. 
Table 15 NP formulations for blends of P9+P10 and P10+P11. 
NP formulation P9 (wt%) P10 (wt%) P11 (wt%) Tt (°C) 
NP9-101 100 0  52 
NP9-102 75 25  58 
NP9-103 50 50  62 
NP9-10 25 75  64 
NP9-105 0 100  65 
NP10-111  100 0 64 
NP10-112  75 25 67 
NP10-113  50 50 70 
NP10-114  25 75 72 
NP10-115  0 100 77 
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Figure 43 Normalised transmittance data for the NP blends of A) P9+P10 and B) P10+P11. A 
sharp transition was observed for each NP type across all the blends. NP suspensions (1 
mg/mL) were heated at a rate of 0.5 °C/min and measured every 0.5 °C.  
As shown in Figure 43 there was complete cooperativity between each 
polymer within the blended polymer NPs as each NP showed one distinct Tt. 
As there was only one transition observed it can be concluded that each 
polymer is well mixed with the other within each set of NPs. The Tts noted for 
  
135 Tuning the aggregation temperature of thermoresponsive nanoparticles 
NP10-11 blends was 64 °C through to 77 °C and the onset of Tt for each blended 
NPs was found to increase by 3-4 °C upon moving through the series of NP 
formulations (NP10-111-5). When the Tt from both these sets of blended NPs 
was plotted versus the OEGMA content a linear relationship could again be 
observed, Figure 44. 
 
Figure 44 Positive linear relationship of OEGMA content from NP blends NP9-10 and NP10-11. 
For characterisation, a sample of the NPs was removed and freeze-dried from 
water prior to dissolution in chloroform to enable NMR analysis of the 
polymer composition. As shown in Table 16 the polymer composition of the 
blended NPs agreed well with the theoretical composition based on the 
mixing ratios of the two polymers (P10+P11).  
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Table 16 Polymer composition within the blended NP formulations NP10-11 as determined by 
1
H NMR. 
NP blend P10 (wt%) P11 (wt%) % OEGMAtheo %OEGMANMR 
NP10-111 100 0 30.1 31.5 
NP10-112 75 25 33.5 33.9 
NP10-113 50 50 36.9 38.0 
NP10-114 25 75 40.4 41.9 
NP10-115 0 100 43.8 45.4 
 
The linear correlation observed between OEGMA percentage and the cloud Tt 
partially refutes the data observed by previous studies. Paris et al. 
demonstrated some cooperativity between different polymer chains 
influencing Tt upon mixing PEGMA polymers in aqueous solution although the 
P(OEG8-9MA)-P(glycidyl methacrylate) produced two distinct transitions above 
equimolar mixes and one transition below.183 They hypothesised this was due 
to the first polymer transition hindering the observation of the two transitions 
at lower ratios; when the concentration of the polymer with lower LCST 
dominated, the less abundant copolymer collapsed on the aggregates of the 
other copolymer, so that in this second collapse, an increase of the optical 
density was not observed.  
To date the mixing of polymer blends and assembling into mixed polymer NPs 
has not been shown. The constraining of two polymers into NPs may 
elucidate why only one transition is observed independently of the molar 
ratio of mixing. If there was a large enough difference in molar mass between 
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the two polymers the lower molar mass polymer will be unlikely to influence 
the overall aggregation of the NP suspension as the higher molar mass 
polymer will either retain hydrophilic state (if it is the higher Tt polymer) or 
will collapse to from large hydrophobic regions (if it is the lower Tt polymer) 
to stimulate aggregation of the suspension which the lower molar mass 
polymer will be unable to inhibit. Steric hindrance is also likely to play its part 
within the phenomenon as the higher the degree of steric hindrance around 
each polymer on the corona of NPs (in the coiled state) the less likely each 
polymer chain is going to be able to undergo the coil-to-globule transition 
independently of the neighbouring polymers. If these polymers were to 
behaving independently of one another and no cooperative behaviour then 
there would be two Tt points observed, however this is clearly not the case as 
one transition is observed in all cases. 
The data in this chapter does agree to an extent with Ieong et al. who showed 
that there was some cooperativity in the Tt tuning process when PEGMA 
polymers with a small change in independent Tt were blended (Tt 7 °C).
177 
However they determined this not to be true cooperativity due to the shift in 
Tt of each blend being insufficient to what should have been observed based 
on the blending ratios. 
Conjugating PEGMA to gold nanoparticles however has also been shown to 
have some tuning ability but Gibson et al determined this was due to the size 
of the particles. 182 They showed an inverse relationship between particle size 
and LCST with the larger Au NPs demonstrating lower Tt. To ensure particle 
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size did not influence our findings each formulation was measured to ensure 
consistent size of NPs. As an example the DLS sizing of the NP10-11 blends are 
shown in Figure 45. 
 
Figure 45 Size measurements of each NP10-111-5 obtained by DLS (NP10-111-5 formed from 
mixing P10+P11, Table 15). The measurements show the consistent size of each NP 
formulation used for Tt analysis. The size shown is from at least 7 measurements of each 
sample  
The NPs assembled were very consistent in size as shown by the DLS intensity 
measurements all overlapping for each blend. Therefore it is likely that it is 
the ratio of polymer blends used, and hence the DEGMA:OEGMA content, 
that tunes the Tt in both blended and non-blended polymer NPs. 
In order to ascertain whether the effect was due to the polymers being 
constrained within blended NPs or not, mixtures of single component NPs 
were analysed. 
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4.3.4  Comparison with preformed nanoparticle blends 
Previous studies showed that tuning can be obtained through mixing 
preformed nanoparticles, instead of mixing polymers before nanoparticles 
formation.177 Therefore it was decided to evaluate the blending of NPs and 
compare with the data obtained for the polymer blend NPs. P6, P7 and P8 
were chosen as they had previously shown Tt tuning ability when mixed. 
Preformed NPs were mixed in the same ratios as before for polymer blend 
NPs (i.e. 75:25, 50:50 and 25:75 vol%), Table 17.  
Table 17 Formulation of the NP blends of NP6-7 and NP7-8.  
NP blend 
formulation 
NP6-71 
(vol%) 
NP6-75 
(vol%) 
NP7-81 
(vol%) 
NP7-85 
(vol%) 
Tt (°C) 
MNP6-72 75 25   29 
MNP6-73 50 50   30 
MNP6-74 25 75 -  33 
MNP7-82 -  75 25 41 
MNP7-83   50 50 43 
MNP7-84   25 75 45 
 
The results obtained for these NP mixtures are shown in Figure 46. Similar 
changes in the optical density and transmittance data was observed as for the 
polymer blend NPs; as the ratio of NPs with higher Tt increased compared 
with the lower Tt NPs the recorded Tt increased also. In all the NP blends 1 
transition was noted which shows that the NP mixture was behaving as one 
and not as two separate entities showing their individual Tt. However the 
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optical density and transmittance curves do show a more gradual onset of the 
cloud point. It can be hypothesised that as the lower Tt NPs begin to lose 
colloidal stability upon reaching their Tt the NPs within the suspension of a 
higher Tt stabilises the suspension for a time until the suspension reaches full 
aggregation. 
  
 
Figure 46 Optical density and transmittance data for the NP blends formed from NP mixtures of NP6-7+NP7-8. A) optical density data for NP6-7 mixtures. B) Normalisation 
of the Abs data from A. C) Normalised transmittance data of data from A.  D)-F) as for A)-C) but with the NP7-8 mixtures. NP suspensions (1 mg/mL) were heated at a 
rate of 0.5 °C/min and measured every 0.5 °C.  
 
 
 
4.4   Conclusions 
Here it has been demonstrated that the transition temperature of PLA-b-
P((DEGMA)-stat-(OEGMA)) nanoparticles can be tuned by altering the ratio of 
DEGMA:OEGMA within the thermoresponsive corona of the NPs similar to 
that of P((DEGMA)-stat-(OEGMA)). However the Tt was found to be slightly 
higher than for the PEGMA polymer alone. For the first time it was shown 
that there was a cooperative process involved in tuning the Tt of blended 
polymer NPs. The constrained nature of the mixed polymers within the NPs 
allows for improved control over the Tt tuning than PEGMA polymer blends. A 
similar outcome was noted when preformed NPs were blended in the same 
ratios as for the polymer blend NPs although with a more gradual onset of full 
aggregation.
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5  Assessing the targeting capabilities of the thermoresponsive 
nanoparticle system in vitro 
5.1  Introduction 
The in vitro testing of formulations is one of the most important steps in the 
development of any successful cancer cell targeting nanoparticle (NP) system. 
Not only should the formulation itself not be toxic to cells, due to the 
possibility of the NPs coming into contact with healthy cells, but, it is also 
crucial to develop ways of targeting these new therapies to tumour cells 
specifically, safely, and efficiently, not only to enhance anti-tumour efficacy 
but also to reduce uptake into healthy tissues.  
The discovery of the enhanced permeation and retention (EPR) effect nearly 
three decades ago by Maeda and Matsumura revolutionised the way 
scientists thought about the field of drug delivery.184 The key mechanism for 
the EPR effect in solid tumours, when applied to macromolecules, more 
recently has been found to be retention. Low-molecular weight compounds 
were shown to be returned to the circulatory system via diffusion, whereas 
macromolecules above 40 kDa were retained within the interstitial space.185 
Exploitation of the EPR effect offers the opportunity for macromolecule and 
particle combinations to act as an alternative to the conventional small 
molecule chemotherapeutic drugs, which generally have poor 
pharmacokinetic and bioavailability profiles. The first PEG-protein conjugate 
(Adagen) entered the market in 1990, this was followed three years later in 
1995 by the first anti-cancer liposomal formulation (Doxil and Abelcet) being 
approved and the first protein-based nanoparticle delivery system (Abraxane) 
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gained approval in 2005.186 More recently the first thermoresponsive particle 
treatment for cancer therapy has entered phase III trials.106 The treatment, 
ThermoDox®, is a heat-sensitive liposome which is used to encapsulate 
doxorubicin and deliver it in a burst effect when the temperature is raised to 
a specific temperature. At this temperature the liposome rapidly changes its 
structure which allows the doxorubicin to escape, Figure 47.187 ThermoDox® 
has shown efficacy in primary liver cancer (hepatocellular carcinoma, or HCC) 
in phase III trials and is currently being evaluated in phase II trials for patients 
with recurring breast cancer. 
 
Figure 47 Comparison of the in vitro and in vivo data from the development of 
ThermoDox®. The treatment was shown to rapidly deliver doxorubicin to the tumour in 
vivo upon raising the temperature beyond the point of liposomal stability. Figure 
reproduced from Celsion website.
187
  
The development of delivery systems which are capable of targeting tumour 
tissues by two methods, i.e. EPR effect and stimulus/targeting ligand, 
increases the likelihood of higher uptake and thus better pharmacokinetics 
with fewer side effects from off target drug release. 
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The design of the targeted nanoparticle system in this study was based on the 
correct size to passively target tumour sites via the EPR effect and targeting 
the folate receptor on tumour cells. The targeting of the folate receptor (FR+) 
has often been referred to as a Trojan horse approach as molecules 
conjugated to folate are transported stealthily into FR+ cells. Folic acid shows 
a very high affinity (KD ~ 10
-10 M) for the cell surface orientated receptor.94,95 
As the folate rapidly binds with its receptor, internalisation occurs via an 
endocytic process.13 The folate receptor is overexpressed on many cancer 
cells (e.g. ovarian, lung, breast, endometrial, renal and colon)188 which makes 
it a very useful target for drug delivery.  
With the advantages of using folic acid, e.g. low molecular weight, stability to 
solvents, lack of immunogenicity and high affinity for its receptor, it is of no 
surprise that there have been many studies on using this ligand to target 
nanoparticles to tumour sites.189-193 A similar approach was taken for the NP 
system under study in this work; the folate was attached to a PEG chain which 
acted as a spacer between the targeting ligand and the PLA core. This was due 
to previous studies showing that by attaching the folate to a PEG linker 
prevents occlusion of the folate if it was attached directly to the core of any 
particle.194,195 The advantage of the NP system studied here is that the folate 
ligand would only be ‘visible’ to the receptor upon heating the NP beyond the 
LCST of the thermoresponsive corona of the NP, Figure 48. 
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Figure 48 Design of the NP system under study 
As the folate receptor is only able to target its receptor upon heating the off-
site targeting is reduced. Although the presence of the receptor in healthy 
cells is low196 any reduction in off-site targeting would be a huge advantage 
for cancer therapy and patient health. 
Within this chapter the testing of the NP system aims to show whether raising 
the temperature of the cell environment above NP Tt stimulates uptake. Also, 
whether the addition of folate targeting can enhance the NP uptake and if so 
does the length of PEG spacer affect the ability of the folate to target its 
receptor. 
5.2  Methods 
5.2.1  Cell culture 
HCT116 (colon cancer, folate receptor negative) and MCF-7 (breast cancer, 
folate receptor positive) cell lines were chosen for the study of the drug 
delivery nanoparticles. 
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Both cell lines were cultured in RPMI medium and the medium was replaced 
every two – three days as needed (10 mL). The cells were split once 80% 
confluency had been reached. 
5.2.1.1  Cell passaging 
5 mL of sterile EDTA was added per flask to wash the cells prior to adding 5 
mL of trypsin and incubating for 5 minutes (until cells had detached) at 37 °C 
and 5% CO2. Once the cells were detached 5 mL of RPMI media was added 
and the cell suspension was centrifuged at 1500 rpm for 5 minutes The 
resulting cell pellet was resuspended in 5-10 mL RPMI media and 10 μL of the 
suspension was used for cell counting. The splitting ratio for both cell lines 
was 1:5. 
The cells were cultured in folate negative RPMI medium for at least two 
passages prior to being used for any studies.  
5.2.1.2  Cell counting 
The 10 µL of cell suspension was diluted with 10 µL trypan blue solution and 
cells were counted using a haemocytometer. To determine the number of 
cells the following equation was used: 
𝑐𝑒𝑙𝑙 𝑛𝑢𝑚𝑏𝑒𝑟(𝑚𝐿−1) = (𝑎𝑣𝑒𝑟𝑎𝑔𝑒 𝑐𝑒𝑙𝑙 𝑐𝑜𝑢𝑛𝑡)𝑥 2 𝑥 10,000 
5.2.2   Cytotoxicity assays 
5.2.2.1  Lactate Dehydrogenase assay 
Flat bottomed 96 well plates were seeded with 1x104 cells/well for 24 h in 
folate free RPMI media at 37 °C and 5% CO2. After 24 h the media was 
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removed and replaced with NP dilutions (200 μL of concentrations from 1 – 
10 mg/mL) in folate free RPMI including two lanes with no NPs added for 
spontaneous and maximum LDH release measurements. The plates were 
incubated at 37 °C under a 5% CO2 atmosphere for 24 h. After 24 h LDH lysis 
buffer was added (10 μL) to lane of maximum LDH release and incubated for 
45 min. 50 μL of the solution from each well was removed and added to new 
96 well plate, to this 50 μL of LDH assay buffer was added (Pierce™ 
ThermoScientific LDH assay kit) incubated for 30 min. The absorbance of each 
well was analysed using a visible light plate reader at 490 nm and 680 nm 
(background). 
% 𝑐𝑦𝑡𝑜𝑡𝑜𝑥𝑖𝑐𝑖𝑡𝑦
=  
𝑁𝑃 𝑡𝑟𝑒𝑎𝑡𝑒𝑑 𝐿𝐷𝐻 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 − 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝐿𝐷𝐻 𝑟𝑒𝑙𝑒𝑎𝑠𝑒
𝑚𝑎𝑥𝑖𝑚𝑢𝑚 𝐿𝐷𝐻 𝑟𝑒𝑙𝑒𝑎𝑠𝑒 − 𝑠𝑝𝑜𝑛𝑡𝑎𝑛𝑒𝑜𝑢𝑠 𝐿𝐷𝐻 𝑟𝑒𝑙𝑒𝑎𝑠𝑒
 𝑥 100 
5.2.2.2  Resazurin assay (alamar blue) 
Black 96 well plates were seeded with 1x104 cells/well for 24 h in folate free 
RPMI media at 37 °C and 5% CO2. After 24 h the media was removed and 
replaced with NP dilutions (200 μL initial concentrations from 0.1 – 10 
mg/mL) in folate free RPMI including a lane for ‘100% cell death’ (DMSO 
treated) and ‘100% cell live’ (media only) controls. The plates were incubated 
at 37 °C and under 5% CO2 atmosphere for 24 h. To each well 50 μL 44 μM 
resazurin in phenol-red free HBSS was added and incubated at 37 °C and 5% 
CO2 for 90 minutes. Fluorescence (λex= 530nm; λem= 590nm) determined and 
% metabolic activity determined by normalising between 100 % death lane (0 
% metabolism) and 100 % live lane (100 % metabolism). 
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5.2.3  Time dependent uptake 
6 well plates were seeded with 2.5x105 cells/ well for 24 h. The media was 
removed and replaced with 100 μg/mL rhodamine labelled nanoparticle 
suspensions in folate free RPMI media. In each plate R5%, FAR5%, R12% and 
FAR12% were added. For each time point a plate was removed from 
incubator and the NP suspension was removed, the cells washed with cold 
NaN3 (5 mM) then warm trypsin was added to remove cells from the well-
plate surfaces for analysis. The harvested cells were washed twice with PBS 
before being fixed with 4% PFA in PBS. For each time point a separate plate 
was used and processed in the same manner as each other. 
5.2.4  Temperature dependent uptake 
6 well plates were seeded with 2.5x105 cells/ well for 24 h. The media was 
removed and replaced with 100 μg/mL rhodamine labelled nanoparticle 
suspensions in folate free RPMI media. To control the temperature two 
incubators were used, set at 22 °C and 37 °C, both under a 5% CO2 
atmosphere. Each plate was placed in the respective incubator dependent on 
the temperature of choice for the experiment for 3 h. 
 The wells were then washed quickly with cold 5 mM sodium azide to inhibit 
any exocytosis then 500 μL trypsin was added to detach the cells which were 
recovered by centrifugation (3,500 r.p.m. for 3 minutes), washed with cold 
PBS twice and fixed with 4% paraformaldehyde ready for flow cytometry 
measurements. 
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5.2.5  Folate dependent uptake 
24 well plates were seeded with 1.5x105 cells/well for 24 h in folate free RPMI 
media. After 24 h the media was removed and replaced with media 
containing varied concentrations of free folic acid (0, 100, 200, 500, 750 and 
1000 μM in 500 μL) for 2 h. This media was then replaced with media 
containing the same concentration of free folic acid + 100 μg/mL of 
rhodamine labelled nanoparticles (500 μL). The plates were incubated at 37 
°C and under a 5% CO2 atmosphere for 3 h. The wells were then washed 
quickly with cold 5 mM sodium azide to inhibit any exocytosis then 500 μL 
trypsin was added to detach the cells which were recovered by centrifugation 
(3,500 r.p.m. for 3 minutes), washed with cold PBS twice and fixed with 4% 
paraformaldehyde ready for flow cytometry measurements. 
The above protocol was repeated for fluorescent microscopy studies in a 96-
well plate (seeded at 1x104 cells/well for 24 h). However the cells were not 
trypsinised and Hoechst 33342 was added prior to fixing to stain the DNA of 
the cells.  
For confocal microscopy 8 chamber borosilicate glass slides were seeded with 
5x104 cells/chamber for 24 h. Two wells were incubated with folate free 
media with a further two incubated with media containing 500 μM folic acid 
for 2 h. The media was then replaced with media (500 µL) containing 100 
μg/mL rhodamine labelled NPs for 3 h. The cell nuclei were then labelled with 
Hoechst 33342 after removing NP suspensions. The cells were washed with 
PBS and fixed with 4% paraformaldehyde. Wells were imaged using a 40X dry 
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objective and the image plane was set to image through the middle of the cell 
by focusing on the nuclei.   
 
5.3   Results and discussion 
To determine the effectiveness of the nanoparticle system in-vitro 3 key areas 
were investigated: 
1. The effects of NPs on cell metabolism and membrane integrity 
2. Temperature dependent uptake of the NPs 
3. Folate dependent uptake of the NPs 
 
Figure 49 Structure of P12 and the general structure for PLA-PEG-folate polymers used in 
Chapter 5  
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Table 18 Nanoparticle formulations investigated throughout Chapter 4 
NP formulation 
PLA-PEGx-
folate (mg) 
PLA-PEGx 
(mg) 
Thermoresponsive 
polymer (P12) (mg) 
R5% 
(PEG450 linker) 
 5 45 
FAR5% 
(PEG450 linker) 
5  45 
3kR5%  
(PEG3k linker) 
 5 45 
FA3kR5% 
(PEG3k linker) 
5  45 
10kR5% 
(PEG10k linker) 
 5 45 
FA10kR5% 
(PEG10k linker) 
5  45 
 
5.4  Effects of nanoparticles on cell metabolism and membrane 
integrity 
Two assay types were used to determine the toxicity of the NPs. Firstly, 
resazurin assay was used which is an assay for measuring the metabolic 
activity of the cells after exposure. 
Resazurin is converted to a fluorescent molecule (resorufin) in metabolically 
active cells, Figure 50. By measuring the fluorescence of the wells and 
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comparing this against wells containing cells which have not been exposed to 
NPs the metabolism of the exposed cells can be calculated. 
 
Figure 50 Metabolism of resazurin to resorufin in healthy cells 
For the metabolic activity testing NPs with Tt above and below 37 °C were 
analysed. This was to determine whether the NPs with their polymer shell in 
their chain-extended (more hydrophilic) or chain-collapsed (more 
hydrophobic) state had any effect on the cells metabolic activity. The NPs 
were incubated for 24 h at 37 °C with concentration of NPs 0.1 – 10 mg/mL.  
Cells exposed to NPs with a Tt below 37 °C (thus in colloidally unstable 
hydrophobic state) showed a lower cell metabolism than those exposed to 
NPs with Tt > 37 °C, Figure 51. The metabolic activity differences between 
each cell line were negligible, with the metabolic activity being > 50 % for 
each formulation < 5 mg/mL. 
 
 
 
Figure 51 Resazurin assay showing percent cell metabolism for HCT116 (A) and MCF-7 (B) 
cell lines exposed to varied range of NP concentrations, metabolism calculated against 
healthy unexposed cells. Cells were exposed for 24 h at 37 °C prior to analysing. Results 
shown are for N=4. NPs are shown to not have an adverse effect on cell metabolism in 
either cell line below 5 mg/mL.  
 
 
In order to investigate further the effects on cells of the NPs (< 5 mg/mL) a 
Lactate Dehydrogenase (LDH) assay was performed. This assay differs from 
the resazurin assay in that it is used to measure how “leaky” the cell 
membranes are. The permeability of cell membranes increases as they 
become necrotic, therefore the quantity of LDH released from the cell will 
increase with the permeability of the membrane. The quantity of LDH present 
can be analysed colorimetrically, Figure 52. 
 
Figure 52 Schematic of the determination of LDH content by the colorimteric analysis of 
formazan product 
The NPs were tested from 1 – 10 mg/mL again for 24 h replicating the 
resazurin assay conditions. 
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Figure 53 LDH assay showing percent LDH release for HCT116 (A) and MCF-7 (B) cell lines 
exposed to varied range of NP concentrations. LDH release calculated against healthy 
unexposed cells and 100% LDH release (cells treated with trigene). Cells were exposed for 
24 h at 37 °C prior to analysing. Results shown are for N=4. NPs are shown to not have an 
adverse effect on LDH release in either cell line below 4 mg/mL.  
For both R5% and FAR5% the %LDH release was found to increase when the 
concentration of NPs was raised above 4 mg/mL, Figure 53. The R12% and 
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FAR12% NPs showed a different trend however with no % LDH release noted 
above the spontaneous control for all concentrations of NPs. This may be due 
to the NPs not causing any detrimental effect on the cell membrane as the 
NPs are in their non-collapsed hydrated state therefore not interacting with 
the cell membrane. The 5% NPs, with a Tt of 32 °C, were in their collapsed 
non-hydrated state and thus would be interacting with cell membranes due 
to the hydrophobicity of both. This interaction at high concentrations of NPs 
is likely to be the reason for the leakage of LDH observed. An alternate reason 
for the lack of LDH release observed for the 12% NPs could be due to small 
quantities of copper present from the polymerisation process. It has been 
suggested in literature that copper can cause inactivation of LDH,197 this 
would have to be tested further to fully comprehend the reason behind the 
lack of LDH release. 
These two assays showed that both types of NPs regardless of their Tt induced 
limited adverse effects on the cells when the concentration was kept below 5 
mg/mL. 
As the NPs were shown to be well-tolerated by the selected cells at lower 
concentrations the next stage was to determine the rate of uptake of the NPs. 
5.5  Time Dependent Uptake 
For rate of uptake studies, the cells were dosed with identical concentrations 
of NPs (100 µg/mL) and at each time point (between 20 and 180 minutes) 
cells were harvested for analysis by the addition of trypsin to the well. One 
well was chosen per time point and the uptake was measured over 3 h. 
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Each set of NPs showed increased uptake over time in the HCT116 cell line, 
with R5% NPs uptake reached a maximum after 90 minutes, the remaining 
NPs were all showing increasing uptake up to the final time-point at 3 h, 
Figure 54. Both types of thermoresponsive NPs were taken up regardless of 
whether they were expected to be in their hydrophilic/hydrophobic state: this 
will be further investigated in section 5.6  
 
 
 
 
Figure 54 Time dependent uptake of NPs in HCT116 cell line from 20 – 180 minutes, NPs 
were added at T0 100 µg/mL. Cells were harvested for flow cytometry using trypsin and 
fixed with 4% PFA in PBS. A) R5%. B) FAR5%. C) R12%. D) FAR12%. Results representative of 
3 independent experiments.  
 
 
The MCF-7 cell-line showed similar results to the HCT116 cell line in that the 
uptake of both R12% and FAR12% NPs increased up to the 3 h timepoint, 
Figure 55. The R5% NPs uptake however appeared to reach a maximum after 
60 minutes compared to the 90 minutes as described above. 
 
Figure 55 Time dependent uptake of NPs in MCF-7 cell line from 30 – 180 minutes, NPs 
were added at T0 100 µg/mL.Cells were harvested for flow cytometry using trypsin and 
fixed with 4% PFA in PBS. A) R5%. B) FAR5%. C) R12%. D) FAR12%.  
A further study was carried out to determine how long the NPs remained in 
the cells once the NP suspension was removed from the cells. The premise for 
this study was to determine whether the NPs were being exocytosed or had 
the opportunity to remain in the cell for a prolonged period of time.  
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NPs were added to the cells (MCF-7 and HCT116) for 3 h then the NP 
suspension was removed using a pipette. For time point 0 the cells were 
harvested as soon as NPs were removed however for each additional time 
point the chosen well was washed twice with warm HBSS and replaced with 
warm HBSS. At each time point the contents of a well were trypsinised and 
fixed with 4% PFA in PBS.  
 
  
 
Figure 56 HCT116 flow cytometry data for the residency time of NPs within cells after removal of NP suspension. A) R5%. B) FAR5%. C)R12%. D) FAR12%. For each NP 
formulation the level of NPs in the cells did drop over time however there were at least 50% of the NPs remaining 80 minutes after exposure, by fluorescence. At least 
15,000 events were recorded for each sample.  
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Figure 57 MCF-7 flow cytometry data for the residency time of NPs within cells after removal of NP suspension. A) R5%. B) FAR5%. C)R12%. D) FAR12%. For each NP 
formulation the level of NPs in the cells decreased over time however there were at least 50% of the NPs remaining 80 minutes after exposure, as demonstrated by 
quantitation of fluorescence. At least 15,000 events were recorded for each sample.  
 
 
As expected the fluorescence decreased with each time point up to 80 
minutes after exposure, Figure 56 and Figure 57. Upon further analysis of the 
data there was between 51 – 81% of the initial quantity NPs taken up 
remaining after 80 minutes, however there was no observable trend between 
type of NP being exocytosed and amount remaining within the cells, Table 19. 
Table 19 Quantity of NPs remaining within cells 80 minutes after exposure 
NP type HCT116 MCF-7 
R5% 73% 55% 
FAR5% 81% 63% 
R12% 60% 51% 
FAR12% 52% 67% 
 
It has been shown previously that shape and size of NPs is important on their 
exocytosis processes;198,199 however the NPs studied above for time 
dependent uptake were all of a similar size and spherical in morphology. 
Panyam et al. noted that PLGA NPs of ~97 nm were exocytosed much slower 
than small molecule marker (Lucifer yellow) with approximately 65 % of the 
initial quantity of NPs exocytosed after 30 minutes.199 When these results are 
compared with those of poly(methyl methacrylate)-block-poly(polyethylene 
glycol methyl ether methacrylate) NPs similar results were obtained however 
these NPs were only ~25 nm in diameter.200  
This data when compared with that shown for the NPs under study here it can 
be concluded that the NP exocytosis is relatively slow (when compared with 
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small molecules) and that this is positive for the use as a drug delivery vehicle. 
The longer the NPs remained in the cells the more likely sufficient drug would 
be released to kill the cell. It also allowed for the knowledge that there would 
be very little exocytosis occurring during processing of the cells between 
washing and fixing for flow cytometry and microscopy measurements 
minimising any error in the analysis. 
The initial studies of both toxicity and time dependent uptake allowed for the 
parameters to be distinguished for further examination of the NP system. 
 
5.6  Thermoresponsive Dependent Uptake 
The nanoparticles formulated for these assays were expected to show 
temperature-dependent uptake based on prior assays.48,49,173 When the 
temperature is raised beyond the Tt and the water molecules bonded to the 
polymers keeping the NPs in solution begins to dissociate from the DEGMA 
and OEGMA units in the polymer backbone the NPs should show a higher 
uptake. This is due to the NPs increasing their hydrophobicity which would 
make them more susceptible to non-specific endocytosis due to both the 
interactions with the hydrophobic cell membrane and protein adsorption. To 
test this hypothesis NPs were incubated with cells both above and below their 
Tt for 3 h and analysed for uptake using flow cytometry. 
The R5% thermoresponsive polymer was used for all further testing as the Tt 
of NPs assembled from this polymer was ~ 32 °C, thus by incubating at room 
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temperature (22 °C) and 37 °C (usual incubator temperature) the NP uptake 
could be assessed above and below the Tt. All testing was carried out within 
an incubator at chosen temperature with a 5% CO2 atmosphere. 
Firstly, the colon cancer cell line, HCT116, was incubated with NPs (100 
µg/mL, far below the toxic limit) for 3 h at each temperature. The NPs used 
contained either the PEG450 or PEG3k linker i.e. (FA)R5% and (FA)3kR5%. 
The uptake of the NPs was found to increase (by almost double) for each type 
of NPs (R5% and 3kR5%) when the incubation temperature was raised from 
22 °C to 37 °C, Figure 58. This increase implied that the higher uptake was due 
to the NPs transitioning to their colloidally unstable hydrophobic phase or 
that with the increased temperature the cells were more stable and enough 
energy present to increase NP endocytosis. In order to determine whether 
this was inherent only to the HCT116 cell line the experiment was repeated 
with the breast cancer cell line MCF-7, which over-expresses the folate 
receptor.190,201,202  
  
 
Figure 58 Flow cytometry measurements of HCT116 cells incubated with NPs at 22 °C  (RT - green) or 37 °C (red). A) R5%. B) FAR5%. C) 3kR5%. D) FA3kR5%. For each 
type of NP (A-D) the median fluorescence (uptake) almost doubled when the incubation temperature was raised from 22 °C – 37 °C. At least 30,000 cells were analysed 
and the results above are representative of at least two repeats.  
 
 
Similar results regarding NP uptake were observed for the MCF-7 cell line, 
Figure 59. For each formulation the uptake had again doubled upon 
increasing the temperature beyond the NPs Tt. There may however be 
another cause for the difference in rate of uptake; that could be due to the 
cells being out with their normal incubation conditions, at room temperature, 
and therefore less energy available to be used for the endocytosis of NPs. In 
order to determine whether this could be the cause of the uptake differential 
the uptake experiment was repeated with dextran, known to be a marker for 
uptake and macropinocytosis.203,204 Two types of dextran were used which 
had a molecular weight of 4 kDa and 40 kDa respectively. Each type of 
dextran was tagged with FITC to ensure the uptake could be monitored by 
flow cytometry 
 
  
 
Figure 59 Flow cytometry measurements of MCF-7 cells incubated with NPs at 22 °C  (RT - green) or 37 °C (red). A) R5%. B) FAR5%. C) 3kR5%. D) FA3kR5%. For each type 
of NP (A-D) the median fluorescence (uptake) almost doubled when the incubation temperature was raised from 22 °C – 37 °C. At least 35,000 cells were analysed and 
the results above are representative of at least two repeats.  
  
 
Figure 60 Flow Cytometry data showing the difference in uptake of FITC-dextran at room temperature and 37 °C. A) FITC-dextran 4k HCT116. B) FITC-dextran 40k 
HCT116. C) FITC-dextran 4k MCF-7. D) FITC-dextran 40k MCF-7. For both types of dextran and both cell lines the uptake was shown to double when the temperature 
was raised from RT to 37 °C.  
 
 
The uptake of both types of FITC-dextran resembled that of the 
thermoresponsive NPs, Figure 60. When the cells were incubated at 37 °C the 
uptake was twice that of the dextran incubated with cells at 22 °C. The uptake 
was independent of the cell line used. This result would mean that there is 
likely no thermoresponsive dependent uptake of these NPs. However, it is 
possible that the uptake pathways of NPs and dextran are different thus this 
would require further study. 
To ascertain whether there were NPs which were beginning to aggregate 
earlier than previous thought and hence becoming hydrophobic at 
temperatures around 22 °C, which may explain why the NPs are being taken 
up at both temperatures, R5% NPs were analysed further by DLS. A 100 
µg/mL suspension was tested at increasing temperatures from 20 – 32 °C and 
the radius and counts were recorded. 
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Figure 61 DLS of R5% NPs showing the increase in both size and counts at 29- 30°C. 
  The DLS data showed that there was no increase in the apparent size (and 
thus aggregation state) of the particles until the temperature reached 30 °C, 
Figure 61. Therefore it is not possible that the particles were in their 
collapsed, colloidally unstable state at the lower 22 °C temperature chosen 
for the uptake study. It can therefore be concluded that the NPs were being 
taken up in a manner independent of the chain conformations of the outer 
polymer shell. 
Similar studies have been carried out regarding the thermoresponsive uptake 
of NPs to varying degrees of success. Li et al. used poly(N-
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isopropylacrylamide-co-N,N-dimethylacrylamide-b-lactide) (PID118-b-PLA59) 
NPs which had  a Tt of 39 °C. Uptake measurements were carried out in a N-87 
stomach cancer cell line at both 37 °C and 40 °C.205 The author concluded that 
there was a difference in uptake of 4x between the 37 °C and 40 °C 
measurements. However by studying the flow cytometry data the largest 
point of fluorescence appears to be at 9 h and the uptake has doubled not 
quadrupled. There is also considerable uptake of the NPs below the Tt 
identified for these types of NPs, similar to the data shown in this chapter. 
The microscopy images clearly showed uptake of NPs at both temperatures, 
therefore although there is a temperature enhanced uptake the NPs still 
accumulate below their Tt. This group hypothesised that the NPs below Tt 
were being taken up by endocytosis however when the NPs became 
hydrophobic, above the Tt, the NPs bound with the cell membrane hence the 
enhanced uptake.  
Barhoumi et al. investigated gold NPs coated with a pNIPAAm-co-
polyacrylamide using a peptide targeting agent (hidden below the Tt) to 
determine cell binding.206 The NPs were found to bind to the human umbilical 
vein endothelial cells (HUVECs) below their Tt, however it should be noted 
that above the Au NPs Tt there almost a 3-fold increase in cell interaction 
(24.3 ± 9.3 µg/kg below Tt and 71.4 µg/kg above the Tt). 
Further to these studies a report in literature showed chitosan-g-poly(N-
vinylcaprolactam) NPs (TRC-NPs) being used as a delivery vehicle of curcumin 
to cancer cells.207 The TRC-NPs were found to have a Tt of 38 °C however the 
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cell uptake experiments analysed by flow cytometry were carried out at 37 °C. 
As the NPs were in their hydrophilic state it would be expected that the NPs 
would not show uptake. This was not the case, uptake was observed in both 
cell lines tested, mouse fibroblast (L929) and prostate cancer cell line (PC3), at 
temperature below the Tt of the NPs. The NPs were incubated for 24 h in the 
presence of the cells before being analysed by flow cytometry. Although there 
was a higher uptake of NPs in the PC3 cell line than the L929 cell line both 
showed a higher uptake than for the control cells. Another point of note in 
the flow cytometry data is that for the highest concentration of NPs studied, 1 
mg/mL, the uptake was less than that of the two lower concentrations, 0.2 
and 0.6 mg/mL.  
Although not a thermoresponsive triggered uptake, Nakamura et al. 
investigated the uptake of zinc protoporphyrin NPs with various coronas. 
They observed that even NPs with a hydrophilic PEG corona showed uptake in 
human chronic myeloid leukaemia cells (K562).208 The presence of the NPs 
within the cells at 37 °C and not 4 °C showed that the NPs were taken up in an 
energy dependent process. The authors concluded that the PEG-ZnPP was 
taken into cells via endocytic pathway and subjected to hydrolytic cleavage by 
either protease or esterase inside of, or in the vicinity of, the cells. The results 
of this investigation also agree with the findings of the work in this chapter 
which shows NP uptake in both the hydrophilic and hydrophobic form.  
Each of these four studies has shown either cell uptake or interaction with the 
cell membrane of NPs below their Tt / hydrophilic state. Comparing this data 
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with that shown for the PLA-b-P(DEGMA-stat-OEGMA) NPs above it can be 
concluded that depending upon a temperature switch alone to trigger NP 
uptake is not a consistently reliable method for targeted drug delivery to 
cancer cells.  
As it was determined the uptake of NPs was due to an energy dependent 
process and that the thermoresponsive nature of the NPs did not lead to an 
enhanced uptake the use of folate was investigated as a method of targeting 
and increasing the uptake. 
5.7  Folate Dependent Uptake 
As there was no observable difference in the uptake of NPs, whether they 
were incubated above or below their transition temperature, the use of folate 
as a targeting agent was investigated. The interest of these NPs would be 
their “hide-and-reveal” capabilities; this involved the folate tag being 
obscured by the extended PEGMA corona of the NP. Once the Tt is reached 
the PEGMA corona was expected to collapse, thus revealing the folate tag to 
target the folate receptor over expressed on some cancerous cells. 
To test the possibilities of the “hide-and-reveal” moiety the three lengths of 
PEG linker between the PLA core and folate tag were investigated when 
mixed with the P12. By using the different lengths of linker, which should 
theoretically then be further from the core when the longer PEG chain is 
used, the required length of linker could be determined. 
  
176 
Assessing the targeting capabilities of the thermoresponsive nanoparticle 
system in vitro 
Each of the PLA-PEGx-folate polymers were mixed with the P12 in a 1:9 ratio 
w/w and tested for their uptake capabilities with both HCT116 and MCF-7 
cells. Free folic acid was added in varying concentrations to determine 
whether there was inhibition of uptake when present.168,209,210 
For these experiments, free folic acid (FA) was incubated for 2 h with the cells 
prior to the addition of the folate-NPs. This incubation period was used to 
allow free FA to equilibrate the cells in the wells to the presence FA. The 
subsequent addition of free FA alongside the folate-NPs serves to maintain a 
constant free FA concentration in solution ensuring the cell environment was 
unchanged during addition of NPs. The concentration of NPs applied to the 
cells was kept constant, 100 µg/mL, for each experiment and incubation time 
was 3 h as for previous uptake experiments. After 3 h the cells were 
harvested using trypsin and fixed with 4% PFA in PBS prior to analysing with 
flow cytometry. 
When the NPs were incubated with the HCT116 FR-ve cell line there was no 
observable difference in uptake between the folate tagged and untagged NPs, 
as shown in Figure 62. This result was expected, as with no folate receptor 
expressed on this cell line, the presence of folate on the NPs should not 
enhance the uptake, as there would be no receptor mediated endocytosis.  
  
 
Figure 62 HCT116 folate dependent uptake flow cytometry data. A) R5%. B)FAR5%. C) 3kR5%. D) FA3kR5%. E) 10kR5%. F) FA10kR5%. The uptake was similar for all NP 
types with added folate having no impact on the uptake. Data representative of a minimum of 18,000 events.  
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Figure 63 MCF-7 folate dependent uptake flow cytometry data. A) R5%. B)FAR5%. C) 3kR5%. D) FA3kR5%. E) 10kR5%. F) FA10kR5%. For FAR5% and FA3kR5% there was 
a 100% increase in uptake compared to the untagged versions of the same NPs, there was no difference for the 10k variety. When there was a large amount of free folic 
acid added (750-1000 µM) the uptake of FA3kR5% was inhibited. There was no effect on the uptake of FAR5% and FA10kR5%. Data representative of  a minimum of 
10,500 events.  
 
 
The MCF-7 cell line (FR +ve) when incubated with each type of NP showed 
differences depending on the NP being studied. The two shorter length PEG 
linker NPs, FAR5% (intensity of   ̴ 20 compared with intensity of  ̴ 7 for R5% 
NPs) and FA3kR5% (intensity of   ̴ 20 compared with intensity of  ̴ 7  for 
3kR5%), had more than double the uptake of their non-folate tagged 
counterparts, Figure 63. The FA10kNPs had no difference in uptake with the 
folate tag compared to the untagged (average fluorescence of 12 - 15 for 
both). As the quantity of free folic acid was added to compete with the NPs 
for uptake by folate receptor endocytosis there was a drop in uptake for the 
FA3kNPs compared to the 3kNPs of around 50% ( drop from 18.8 for 0 μM FA 
to 10.8 fluorescence for 1000 µM FA). The concentration of free folic acid had 
to be high, 750 – 1000 µM for there to be any inhibition in NP uptake. The 
addition of free folic acid appeared to have no effect on the uptake of both 
FAR5% and FA10kR5% NPs. 
As there was a considerable increase in the uptake of both FAR5% and 
FA3kR5% in MCF-7 cell line compared to both their non-folate counterparts 
and the uptake of both in the HCT116 cell line the additional uptake was 
attributed to folate receptor mediated endocytosis. It was clear that all types 
of NPs were also being taken up by another energy dependent uptake, as 
there was fluorescence recorded in both cell types for all NPs. 
This data would suggest that when the temperature is raised beyond the Tt of 
the thermoresponsive corona both the PEG450-linked folate and PEG3k-linked 
folate is capable of binding to the folate receptor on MCF-7 cells; with no 
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difference in fluorescence between 10kR5% and FA10kR5% this would 
suggest the folate is not capable of binding to receptor to enhance the 
uptake. A possible cause of this is that the folate bound to the end of the PEG 
chain was embedded within the hydrophobic core of the NP. It has been 
shown that when PLGA-PEG5k-folate was used as a targeted self-assembled 
NP only ~20% of the folate was present on the surface of the NP, the 
remainder was hypothesised to be within the core due to interactions with 
the PLGA.142 
To elucidate further the NP uptake differential, when the folate targeting 
ligand is used, the uptake was visualised using confocal microscopy. 8 well 
chamber slides were seeded with cells for 24 h and the uptake experiment 
was repeated as for the flow cytometry analysed samples. The folate and 
non-folate versions of R5% and 3kR5% were chosen for imaging as they had 
shown an uptake differential unlike the 10kR5% NPs. Each well of cells was 
fixed with paraformaldehyde, after incubation and washing steps with PBS, 
prior to imaging. For the confocal microscopy the image plane was set to cut 
through the centre of the cell by focussing on the cell nucleus. For the 
purposes of the imaging the cell nuclei were stained with Hoechst 33342. 
Within each well that was imaged there was observable uptake across both 
cell lines, shown by the green in Figure 64 (MCF-7) and Figure 65 (HCT116) 
plus zoomed confocal in Figure 66. There was substantial aggregation present 
around the cells incubated with 3kR5% and FA3kR5% for both cell types. This 
is not surprising considering the assays were carried out above the Tt of the 
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NPs. As shown previously, as the temperature is raised above the Tt the NPs 
will begin to aggregate. For both of these NPs the aggregates adhered to the 
hydrophobic glass slide as well as the cell membranes. Even though there was 
considerable aggregation present the NPs were still taken up by the cells. 
There was no obvious localisation of the NPs within the cells and all types 
were spread homogeneously throughout the interior. However this could not 
be fully confirmed without the use of colocalisation imaging. 
 
  
 
Figure 64 Confocal microscopy images of NP uptake (green) with MCF-7 cells. NPs were incubated with cells for 3 h with or without the presence of free folic acid. 
Nuclear staining: Hoechst 33342 (blue). There was uptake observed for all types of NPs including when free folic acid was added. There was noticeable aggregation 
present in all images however this was most noticeable for the 3kR5% NPs. Scale bar 30 µm.  
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Figure 65 Confocal microscopy images of NP uptake (green) with HCT116 cells. NPs were incubated with cells for 3 h with or without the presence of free folic acid. 
Nuclear staining: Hoechst 33342 (blue). There was uptake observed for all types of NPs including when free folic acid was added. There was noticeable aggregation 
present in all images however this was most noticeable for the 3kR5% NPs. Scale bar 30 µm  
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Figure 66 Zoomed confocal images of NP uptake. A) HCT116 FA3kR5% (no added FA) B) 
HCT116 FA3kR5% (+ 1000 µM added FA) C) MCF-7 FA3kR5% (no added FA) D) MCF-7 
FA3kR5% (+ 1000 µM added FA). Sclae bar 30 µm.  
The confocal images confirmed that there was NP uptake across both cell 
types, although the uptake differential between NPs with and without the 
folate tag could not be confirmed. Confocal microscopy as used here is a 
qualitative analytical device and not quantitative as flow cytometry is. 
Therefore without there being a substantial difference in the uptake, confocal 
microscopy can only show where the NPs are located within the cells.  
Previous imaging of P12 NPs (with no targeting ligand present) on HCT116 
cells had confirmed uptake as depth profiling was carried out as shown in 
Figure 67. The arrows within the figure show that the NPs (green) are located 
within the boundaries of the membrane (red) thus proving internalisation. 
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The confocal images taken above were focused through the middle of the 
cells to ensure fluorescence noted from the NPs were those internalised 
within the cells.  
 
Figure 67 Orthogonal projection of a 3D image acquired of HCT116 cells treated with 250 
µg/ml of P12 NPs overnight at 37°C. The arrows point at the internalization of the 
nanoparticles (Green) where its fluorescence can be localised within the boundaries of the 
red membrane. Nuclei: Blue. Scale bars represent 50 µm. Analysis performed by Luana 
Sasso.  
What the images recorded had shown was that the NPs were being taken up 
and not just remaining bound to the cell membrane as is possible due to the 
hydrophobic interactions of NP with cell membrane.154 With the knowledge 
that the NPs were definitely within the cell itself and not around it, the 
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differences observed in flow cytometry data can be confirmed to be 
differences in the NP uptake.  
By taking together the confocal results with the flow cytometry data it can be 
concluded that when the folate targeting agent is visible to the folate 
receptor, NP uptake is enhanced. From the three lengths of PEG spacer 
chosen between the NP core and folate, NPs containing either the PEG450 or 
PEG3k linked folate were suitable for targeting the folate receptor. This 
showed that the targeting polymer was not covered to an extent which 
obscured the folic acid end group upon thermoresponsive corona collapse. 
The NPs containing the PEG10k linker showed no difference in uptake whether 
the folate was present or not. There are two possible reasons for this; either 
the folate is trapped beneath the collapsed NP corona; or the increased PEG 
length resulted in the hydrophobic folic acid moiety being embedded within 
the NP core due to hydrophobic interactions with PLA and thus not available 
for targeting the receptor.142 
5.8  Conclusions 
The observed uptake of thermoresponsive NPs reached their maximum 
uptake between 90 – 180 minutes after application of the NPs. The 
temperature triggered change in surface properties of the NPs did not change 
the extent of uptake to a significant degree compared to the inherent 
temperature change alone. Although this result was unexpected it was in 
agreement with some prior work which had shown both thermoresponsive 
NPs below their Tt were capable of being taken up by cells. The use of a folic 
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acid derivative attached via a PEG linker to the NPs when combined with the 
thermoresponsive polymer enhanced the uptake of the particles in MCF-7 
cells. The uptake of folate targeted NPs doubled when conjugated via PEG450 
and PEG3k spacer compared to the non-folate targeted NPs. When a PEG10k 
spacer was used between NP core and folate no enhancement in uptake was 
observed. 
.
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6  Summary and potential future work 
The principle aim of this thesis was to develop a thermoresponsive polymer 
nanoparticle formulation that was capable of targeting cancer cells in vitro. 
The nanoparticle formulation was to contain a ‘hide-and-reveal’ motif 
designed to only reveal a folate targeting ligand upon heating the formulation 
beyond its transition temperature. The premise behind the ‘hide-and-reveal’ 
motif was to minimise off-site targeting by the folate ligand whilst maximising 
uptake within cancer cells which overexpress the folate receptor. The key 
findings of this thesis are now further discussed. 
Prior to testing the combination of thermoresponsive nanoparticles and 
receptor targeting for enhanced uptake a polymer with a suitable transition 
temperature and a amphiphilic folate tagged polymer was required. The 
synthesis of these was discussed in Chapter 2. After problems synthesising 
PLGA-b-P(OEGMA-stat-PPGMA) with a sufficiently low Tt for cell testing a 
small library of PLA-b-P(DEGMA-stat-OEGMA) polymers were synthesised. 
From the library its was chosen to synthesise two PLA-b-P(DEGMA-stat-
OEGMA) polymers with a DEGMA:OEGMA ratio of 95:5 and 88:12 to allow for 
Tt of the NPs assembled from this polymer to be above and below 37 °C. Both 
these types of polymers were successfully synthesised with a rhodamine tag 
for in vitro testing. In conjunction with the thermoresponsive polymer 
synthesis three PLA-PEG-folate polymers were synthesised with a PEG spacer 
of either 450 Da, 3 kDa or 10 kDa to determine whether this would have any 
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effect on the targeting capabilities of the NPs formed from mixtures of the 
PLA-PEG-folate and thermoresponsive polymer. 
In Chapter 3 a method for the reproducible assembly of the PLA-b-P(DEGMA-
stat-OEGMA)  polymers synthesised in Chapter 1 was developed. The method 
was adapted from a continuous flow/microfluidic process developed within 
the Langer laboratory.143 The method developed in this chapter made use of 
syringe pumps to provide the continuous flow and a T-junction as the mixing 
device thus no microfluidic chip was needed. Nanoparticles assembled using 
the solvent flow method offered enhanced reproducibility in size than those 
assembled by the solvent drop method across all the polymers tested. It was 
determined that the flow rate had a negligible effect on the size of NPs 
produced, this was most likely due to the stabilisation effect of the PEGMA 
chains forming the shell of the NPs. The solvent flow method offered an 
advantage over other nanoparticle formulation method as it was capable of 
assembling nanoparticles at a rate of 600 mg/h, faster than the 84 mg/h 
reported in literature. 
In Chapter 4 possible methods of controlling the aggregation temperature of 
thermoresponsive nanoparticles was investigated. It was demonstrated that 
the transition temperature of PLA-b-P(DEGMA-stat-OEGMA) nanoparticles 
could be tuned by altering the ratio of DEGMA:OEGMA within the 
thermoresponsive corona of the NPs similar to that of P((DEGMA)-stat-
(OEGMA)). For the first time it was shown that there was a cooperative 
process involved in tuning the aggregation temperature of blended polymer 
  
190 Summary and potential future work 
NPs. The constrained nature of the mixed polymers within the NPs allows for 
improved control over the aggregation temperature tuning than PEGMA 
polymer blends. 
In Chapter 5 the thermoresponsive and folate targeted nanoparticle system 
was tested in vitro using MCF-7 and HCT116 cancer cells. It was found in this 
chapter that although the heating of the nanoparticles past their transition 
temperature did not enhance the uptake, the use of folate as a targeting 
ligand did provide a suitable method for enhancing nanoparticle uptake. The 
uptake of nanoparticles was found to double when the folate tag was present 
compared to NPs without the tag. It was found that when the PEG10k spacer 
was used to link the folate to the PLA core of the nanoparticle there was no 
enhancement in the uptake of nanoparticles. 
6.1  Overall conclusion 
This thesis has found that although a temperature switch did appear to show 
enhanced uptake of NPs it is not a simple process; there are many points to 
be investigated before relying on a temperature switch alone as a method of 
enhancing nanoparticle uptake. The findings here have shown that by 
blending a thermoresponsive polymer (PLA-b-P(DEGMA-stat-OEGMA)  with a 
folate tagged amphiphilic polymer (PLA-PEG) nanoparticle uptake can be 
enhanced. With the ‘hide-and-reveal’ motif provided by this blended 
nanoparticle system, the temperature switch allows for the folate ligand to 
only be visible when within the tumour environment; thus offering an 
advantage over nanoparticles which have a targeting ligand always on the 
surface of the particle by minimising any offsite targeting and improving 
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pharmacokinetics. It has been shown by other groups that nanoparticles 
either below their transition temperature or with a hydrophilic shell do show 
non-specific uptake similar to the uptake of particles studied here.34,205,207 
This is a problem area which really needs further study as to the routes of 
uptake of these nanoparticles before any possible widespread use as a 
method of drug delivery. 
This thesis also puts forward a new simple method for assembling polymer 
nanoparticles with a reproducible size and without the need for the assembly 
of microfluidic chips. This method would find use within the pharmaceutical 
industry as it is a relatively cheap method of producing nanoparticles at a 
higher rate than for the more conventional microfluidic chip system (600 
mg/h versus 84 mg/h).  
 
6.2  Potential future work 
The following future work would support that presented within this thesis 
and also progress the use of these types of nanoparticles as a suitable drug 
delivery system for anti-cancer therapy. 
 Determine whether increasing the ratio of folate tagged polymer to 
thermoresponsive polymer within nanoparticle system increases 
targeting efficiency. 
 Use cells with higher folate receptor expression as the MCF-7 cell line 
is known to only have a low expression of the folate receptor.  
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 Ascertain the uptake pathway of the nanoparticles both above and 
below their transition temperature to determine whether the 
different surface properties of the particles affects their 
internalisation. 
 Investigate whether the residency time determined in this body of 
work is sufficient to allow drug to be released which would be capable 
of causing cell death. 
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7  Materials and Equipment 
7.1  Materials 
All materials were used as delivered without any prior purification. 
Sigma-Aldrich 
Tetraethyleneglycol (TEG) ( 99%), 2-bromoisobutyryl bromide (98%), D,L-
lactide, glycolide (>99%), poly(ethylene glycol) methyl ether methacrylate 
(OEGMA) (Average Mn ca. 188, 475 and 500), poly(propylene 
glycol)methacrylate (PPGMA) (Average Mn ca. 375), N,N,N′,N′′,N′′-
pentamethyldiethylenetriamine (PMDTA) (99%), tin (II) 2-ethylhexanoate 
(95%), O-(2-aminoethyl)-O′-(2-azidoethyl)nonaethylene glycol, Roswell Park 
Memorial Institute (RPMI) medium, 2,2’-bypridyl, DMSO-d6 (99.9% D) and 
CDCl3 (99.8% D). 
Alfa Aesar 
Copper(II) bromide (99%), copper (I) bromide (99%) and 2-butanone ( 99%). 
Others 
Amino-PEG-alkyne (Mn 3000 and 10,000 Da, Iris-Biotech GmbH)., folate free 
RPMI media (Gibco). Cell culture flasks and plates (Corning). 8 well chamber 
slides (Lab-Tek II, Thermo Scientific), PD-10 desalting columns (GE healthcare) 
2-(2-(2-azidoethoxy)ethoxy) ethanol was provided by Dr. Johannes 
Magnusson. 
Statistical analysis and graph plotting was carried out using Graphpad Prism 6 
software. 
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7.2  Gel permeation chromatography 
GPC was performed on a Polymer Laboratories GPC 50 system equipped with 
a refractive index detector. Separations were achieved with a pair of PLgel 
Mixed-D (5 μm bead, 7.8 × 300 mm) columns with a matching guard (7.8 × 50 
mm) and chloroform as eluent at a flow rate of 1 mL min-1. Calibration was 
performed using narrow polystyrene standards (Polymer Labs) in the 
molecular weight range 0.13-210 kDa. Molecular weights and dispersity 
values were calculated using Cirrus GPC 3.0 software. All samples were 
dissolved in chloroform prior to analysis. 
7.3  High performance liquid chromatography (HPLC) 
HPLC was performed on a Shimadzu HPLC (LC-20AD pump) equipped with a 
C18 column (Jupiter, 5 μm, 250 x 46 mm, Phenomenex), SPD-M20A UV 
detector and SIL-20A autosampler. Mobile phase was water (A) and 
acetonitrile (B). Method: 10 – 20 % B over 17 minutes, UV detection at 363 
nm.  
7.4  Dynamic light scattering (DLS) 
DLS measurements were carried out on Viscotek Model 802 instrument with 
an internal laser (825-832 nm). Samples were taken from nanoparticle 
suspension in ultrapure water or PBS and at least 7 measurements were 
taken. Results were processed using OmniSize version 3.0. DLS is a non-
invasive technique used to measure the size of particles within a suspension. 
The diffusion coefficients of the particles are measured as they undergo 
random Brownian motion within the suspension. The measured diffusion 
  
195 Materials and Equipment 
coefficients can then be converted to the hydrodynamic sizes by the Stokes-
Einstein equation: 
𝑑(𝐻) =  
𝑘𝑇
3𝜋𝜂𝐷
 
Where d(H) = hydrodynamic diameter, k = Boltzmann’s constant, T = absolute 
temperature, η = viscosity and D = translational diffusion coefficient. 
7.5   Cloud point determination 
Samples were analysed using Beckmann Coulter UV-vis spectrophotometer at 
550 nm and 750 nm. Sample concentration was kept constant for each 
sample and temperature ramped at 0.5 °C min-1 while being measured every 
0.5 °C increase. Absorbance/optical density (A) could be converted to 
transmittance (%T) using the following formula: 
𝐴 = 2 − 𝑙𝑜𝑔10 %𝑇 
7.6  Nuclear magnetic resonance (NMR) 
NMR spectra were obtained from a Bruker 400 Ultrashield at 400MHz and 25 
°C. Each spectrum was analysed using MestReNova v6.0.2.  
7.7  Mass spectrometry 
High resolution mass spectra (HRMS) – time of flight electrospray (TOF ES +/-) 
were recorded on a Waters 2795 separation module micromass LCT platform. 
Samples were prepared in a 1:1 mixture of acetonitrile: water containing 0.1% 
formic acid.  
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7.8  Flow cytometry 
Flow cytometry measurements were made on a Beckman Coulter MoFlo 
Astrios flow cytometer. Samples were analysed using green laser (λex 561 nm, 
λem 620 nm). All analysis was carried out using Kaluza analysis software v1.3. 
7.9  Transmission electron microscopy (TEM) 
5 μL of dilute NP suspensions were mixed with 5 µL 3% phosphotungstic acid 
and placed on Formvar® coated 3 mm 75 mesh copper TEM plate for 5 
minutes, any excess liquid was wicked off using filter paper. TEM images were 
obtained using a FEI Technai 12, Biotwin microscope. 
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